# Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL

https://doi.org/10.1038/s41586-022-05140-y

Received: 29 March 2021

Accepted: 25 July 2022

Published online: 31 August 2022

**Open access** 

Check for updates

Jiqin Zhang<sup>1,8</sup>, Yongxian Hu<sup>2,3,4,5,8</sup>, Jiaxuan Yang<sup>1,8</sup>, Wei Li<sup>6</sup>, Mingming Zhang<sup>2,3,4,5</sup>, Qingcan Wang<sup>6</sup>, Linjie Zhang<sup>1</sup>, Guoqing Wei<sup>2,3,4,5</sup>, Yue Tian<sup>1</sup>, Kui Zhao<sup>7</sup>, Ang Chen<sup>1,6</sup>, Binghe Tan<sup>1,6</sup>, Jiazhen Cui<sup>2,3,4,5</sup>, Deqi Li<sup>6</sup>, Yi Li<sup>2,3,4,5</sup>, Yalei Qi<sup>1</sup>, Dongrui Wang<sup>2,3,4,5</sup>, Yuxuan Wu<sup>1,6</sup>, Dali Li<sup>1,6</sup>, Bing Du<sup>1,6</sup>, Mingyao Liu<sup>1,6</sup> & He Huang<sup>2,3,4,5</sup>

Recently, chimeric antigen receptor (CAR)-T cell therapy has shown great promise in treating haematological malignancies<sup>1-7</sup>. However, CAR-T cell therapy currently has several limitations<sup>8-12</sup>. Here we successfully developed a two-in-one approach to generate non-viral, gene-specific targeted CAR-T cells through CRISPR-Cas9. Using the optimized protocol, we demonstrated feasibility in a preclinical study by inserting an anti-CD19 CAR cassette into the AAVS1 safe-harbour locus. Furthermore, an innovative type of anti-CD19 CAR-T cell with PD1 integration was developed and showed superior ability to eradicate tumour cells in xenograft models. In adoptive therapy for relapsed/refractory aggressive B cell non-Hodgkin lymphoma (ClinicalTrials.gov, NCT04213469), we observed a high rate (87.5%) of complete remission and durable responses without serious adverse events in eight patients. Notably, these enhanced CAR-T cells were effective even at a low infusion dose and with a low percentage of CAR<sup>+</sup> cells. Single-cell analysis showed that the electroporation method resulted in a high percentage of memory T cells in infusion products, and PD1 interference enhanced anti-tumour immune functions, further validating the advantages of non-viral, PD1-integrated CAR-T cells. Collectively, our results demonstrate the high safety and efficacy of non-viral, gene-specific integrated CAR-T cells, thus providing an innovative technology for CAR-T cell therapy.

In recent years, chimeric antigen receptor (CAR)-T cell therapy has rapidly developed and it shows great potential in cancer therapy $1^{-7}$ . Nevertheless, some limitations still remain, including the complicated manufacturing process, high production cost, long preparation time and potential safety concerns of current therapies. The use of virus in CAR-T cell production is one area of concern, as the disadvantages of this approach include an increased risk of tumour development resulting from insertional mutagenesis<sup>8,9</sup>. Furthermore, specific responses to virus-derived DNA tend to impede CAR expression<sup>10,11,</sup> and virus manufacture frequently incurs high costs<sup>12</sup>. Although some strategies, such as using transposon systems<sup>13-16</sup> and mRNA transduction<sup>17-19</sup>, are being exploited to generate CAR-T cells without virus, the low homogeneity of the final products caused by random integration and discontinued CAR expression become additional problems. Recently, several studies have shown that genome editing technologies can be applied to generate locus-specific integrated CAR-T cells by using an adeno-associated virus (AAV) vector as a template<sup>20-22</sup>. Furthermore, one preferential non-viral strategy was proposed to produce T cell products with point mutation correction and precise insertion of the T cell receptor (TCR) element<sup>23</sup>. Thus, to simultaneously solve the disadvantages of virus usage and random integration, here we developed non-viral, gene-specific targeted CAR-T cells through CRISPR–Cas9 and demonstrated their high safety and effectiveness in treating patients with relapsed/refractory B cell non-Hodgkin lymphoma (r/r B-NHL).

#### Characteristics of AAVS1-19bbz cells

First, we sought to optimize the protocol for producing non-viral, gene-specific integrated T cells. A homology-directed repair (HDR) template, in the form of linear double-stranded DNA (dsDNA), was found to achieve high homologous recombination efficiency and cell viability (Fig. 1a and Extended Data Fig. 1a–c). More viable cells carrying a targeted gene integration were acquired when electroporation was carried out in stimulated T cells by applying 800-bp homology arms (Fig. 1b,c and Extended Data Fig. 1d–k). After confirmation of an optimal protocol, for proof of concept, we first chose to target the CAR-expressing cassette to the *AAVSI* safe harbour to evaluate whether this approach would affect the properties of the CAR-T cells. An anti-CD19 CAR sequence containing 4-1BB and CD3 $\zeta$  (named 19bbz) was constructed. The integration efficiency of 19bbz into *AAVSI* was about 10% (up to 19.8%), and the indel percentage ranged from 67% to 87% (Fig. 1d,e and Extended Data Fig. 2a,m,nq). Next,

<sup>1</sup>Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China. <sup>2</sup>Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. <sup>3</sup>Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China. <sup>4</sup>Institute of Hematology, Zhejiang University, Hangzhou, China. <sup>5</sup>Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China. <sup>6</sup>BRL Medicine, Inc., Shanghai, China. <sup>7</sup>PETCT Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China. <sup>8</sup>These authors contributed equally: Jiqin Zhang, Yongxian Hu, Jiaxuan Yang. <sup>52</sup>e-mail: zjqjeremy@163.com; dlli@bio.ecnu.edu.cn; bdu@bio.ecnu.edu.cn; myliu@bio.ecnu.edu.cn; huanghe@zju.edu.cn



**Fig. 1** | **Non-viral**, *AAVS1*-integrated CAR-T cells effectively eliminate tumour cells. a, Specific integration of the CAR cassette into the target locus by homologous recombination through CRISPR–Cas9. **b**, **c**, Percentage of CAR<sup>+</sup> cells (**b**) and number of viable CAR<sup>+</sup> cells (**c**) detected 7 d after electroporation using equimolar amounts of DNA templates with different homology arm lengths (*n* = 2 independent healthy donors). **d**, CAR expression in cells from two representative healthy donors determined 7 d after electroporation. SSC, side scatter. K, ×1,000. **e**, Percentage of CAR<sup>+</sup> cells detected 7 d after electroporation (*n* = 23 independent healthy donors). **f**, Expansion of CAR<sup>+</sup> cells after repeated stimulation with Raji cells. Data are shown as the mean ± s.e.m. (*n* = 3 independent healthy donors). **g**, Median fluorescence intensity (MFI) of CD69, CD137, CD25, PD1 and LAG3 expression in T cells detected after 24 h of co-culture with Raji cells (*n* = 3 independent healthy donors). CD3<sup>+</sup> (untreated T, control) or CD3<sup>+</sup>CAR<sup>+</sup> (LV-19bbz, AAVS1-19bbz) gated cells were analysed. **h**, Cytokine secretion measured by bead-based immunoassay in the supernatant

we comprehensively compared AAVS1-integrated (AAVS1-19bbz) and lentivirus-produced (LV-19bbz) anti-CD19 CAR-T cells. Although the electroporation procedure itself led to some cell damage, T cell expansion was not impaired and high cell viability was detected after thorough recovery (Extended Data Fig. 2b-d). While lentivirus infection resulted in a higher percentage of CAR<sup>+</sup> cells among CD4<sup>+</sup> cells than among CD8<sup>+</sup> cells, integration was unbiased between CD4<sup>+</sup> and CD8<sup>+</sup> cells by the electroporation strategy (Extended Data Fig. 2j). Notably, electroporation increased the ratio of CD8<sup>+</sup> to CD4<sup>+</sup> T cells when compared with lentiviral transduction (Extended Data Figs. 2k and 8d-f), which was consistent with a previous study<sup>23</sup>. We observed that AAVS1-19bbz cells responded to tumour cells as LV-19bbz cells did (Fig. 1f-h and Extended Data Fig. 2e). By contrast, some differences were found in cell marker expression and cytokine secretion. Notably, like LV-19bbz cells, AAVS1-19bbz cells vigorously eradicated tumour cells in vitro and in vivo (Fig. 1i, j and Extended Data Fig. 2f-i).

after co-culture with Raji cells for 24 h. Data are shown as the mean  $\pm$  s.e.m. (n = 3 independent healthy donors). IL-2, interleukin-2; TNF $\alpha$ , tumour necrosis factor  $\alpha$ ; IFN $\gamma$ , interferon- $\gamma$ . i, In vitro cytotoxicity against Raji cells as determined by lactate dehydrogenase (LDH) assay. E/T ratio, effector/target ratio. Data are shown as the mean  $\pm$  s.e.m. (n = 3 independent healthy donors). j, Bioluminescence imaging of tumour cell growth following different treatments on the indicated days after CAR-T cell infusion (n = 5). The radiance scale (p s<sup>-1</sup> cm<sup>-2</sup> sr<sup>-1</sup>) is shown. Immunodeficient mice were injected intravenously with  $2 \times 10^5$  firefly luciferase (ffLuc)-transduced Raji cells, and  $2 \times 10^6$  CAR-T cells were administered intravenously after 5 d. Control samples were electroporated the same as AAVS1-19bbz cells except without single guide RNA (sgRNA) addition. The mean value is shown in **b**, **c**, **e**, *g*. *P* values were calculated by one-way ANOVA with Tukey's multiple-comparisons test (**g**, **h**) or two-way ANOVA with Sidak's multiple-comparisons test (**f**) or Tukey's multiple-comparisons test (**i**).\*\*\**P* < 0.001, \*\**P* < 0.01; NS, not significant.

Taken together, these results demonstrate that the strategy to produce non-viral, gene-specific targeted CAR-T cells is feasible.

#### PD1-19bbz cells outperform LV-19bbz cells

Given that blockage of the PD1–PD-L1 pathway has been reported to improve the anti-tumour activity of CAR-T cells<sup>24–27</sup>, we set out to develop an enhanced type of CAR-T cells by integrating an anti-CD19 CAR sequence into the *PD1* gene (PD1-19bbz) (Fig. 1a and Extended Data Fig. 2m,o–q). CAR expression was observed in about 20% (up to 30.3%) of healthy donor T cells, and a high indel percentage (83– 93%) and PD1 impairment were detected (Fig. 2a–d). PD1-19bbz cells had higher proliferation than LV-19bbz cells after repeated stimulation with PD-L1-expressing Raji cells (Fig. 2e and Extended Data Fig. 2r). As indicated by other reports<sup>28–30</sup>, PD1 disruption did not affect the elevation of activation markers and cytokine secretion to



**Fig. 2** | **Non-viral**, *PDI*-integrated CAR-T cells outperform lentivirusproduced CAR-T cells. a, CAR expression in cells from two representative healthy donors determined 7 d after electroporation. **b**, Percentage of CAR<sup>+</sup> cells detected 7 d after electroporation (*n* = 20 independent healthy donors). **c**, Percentages of CAR integration and *PDI* indels in total T cells detected 7 d after electroporation in five representative healthy donors. **d**, Percentage of cells with PD1 expression detected by flow cytometry in CD3<sup>+</sup>CAR<sup>+</sup> gated cells after 24 h of co-culture with PD-L1-expressing Raji cells (*n* = 3 independent healthy donors). **e**, Expansion of CAR<sup>+</sup> cells after repeated stimulation with PD-L1-expressing Raji cells. Data are shown as the mean ± s.e.m. (*n* = 3 independent healthy donors). **f**, Cytokine secretion measured by bead-based immunoassay in the supernatant after co-culture with PD-L1-expressing Raji cells for 24 h. Data are shown as the mean ± s.e.m. (*n* = 3 independent healthy donors). **g**, In vitro cytotoxicity against PD-L1-expressing Raji cells determined

counteract targeted tumour cells (Fig. 2f and Extended Data Fig. 2l). To fully understand the properties of PD1-19bbz cells, we manufactured CAR-T cells with *PD1* knockout using lentivirus and CRISPR– Cas9 (LV-19bbz\_PD1-KO) and performed parallel assays in various groups. Although expression of some cell markers was different, PD1-19bbz cells in general exhibited similar CAR expression levels and antigen-independent and antigen-dependent tonic signalling as other CAR-T cells (Extended Data Fig. 3). Notably, in comparison with other groups, PD1-19bbz cells showed more robust clearance of tumour cells expressing either high or low levels of PD-L1 (Fig. 2g–j and Extended Data Fig. 4). Collectively, these data indicate that non-viral, *PD1*-integrated CAR-T cells have the potential to more effectively eliminate tumour cells. by LDH assay. Data are shown as the mean  $\pm$  s.e.m. (n = 3 independent healthy donors). **h**-**j**, Immunodeficient mice were injected intravenously with  $5 \times 10^5$  ffLuc-transduced PD-L1-expressing Raji cells, and  $1 \times 10^6$  CAR-T cells were administered intravenously after 5 d. **h**, **i**, Bioluminescence kinetics (**h**) and imaging (**i**) of tumour cell growth following different treatments (n = 4 or 8). Data are shown as the mean  $\pm$  s.e.m. in **h**. Imaging on the indicated days after CAR-T cell infusion and the radiance scale ( $p s^{-1} cm^{-2} sr^{-1}$ ) are shown in **i**. **j**, Kaplan–Meier analysis of survival of the mice in **i**. Control samples were electroporated the same as PD1-19bbz cells except without sgRNA addition. The mean value is shown in **b**, **d**. *P* values were calculated by one-way ANOVA with Tukey's multiple-comparisons test (**f**), two-way ANOVA with Sidak's multiple-comparisons test (**e**) or Tukey's multiple-comparisons test (**g**), or a log-rank Mantel–Cox test (**j**). \*\*\*\**P* < 0.0001, \*\*\**P* < 0.01; NS, not significant.

#### r/r B-NHL treated with PD1-19bbz cells

On the basis of our preclinical experimental data, we then proceeded to carry out a phase 1 clinical trial to evaluate the safety and efficacy of PD1-19bbz cells in treating patients with r/r B-NHL (ClinicalTrials. gov, NCT04213469). Eight patients who had not previously been treated with CAR-T cell therapy were enrolled. In the final infusion products, the average percentages of CAR integration and *PD1* indels were about 20% and 60%, respectively (Extended Data Fig. 5a–e and Supplementary Table 1). The infusion products had a cell viability of greater than 90% and responded to and eradicated tumour target cells in vitro (Extended Data Fig. 5f–h). Low-frequency off-target events at one site in *PHACTR1* (phosphatase and actin regulator 1), identified by



**Fig. 3** | **Non-viral**, *PD1*-integrated **CAR-T** cells potently eliminate tumour cells in patients with r/r B-NHL without serious toxicity. a, Occurrence of CRS and ICANS after treatment. b, Percentage of CAR<sup>+</sup> cells among the peripheral blood T cells of patients on the indicated days before and after infusion. c, CAR copy number in genomic DNA from the peripheral blood of

patients on the indicated days before and after infusion. **d**, Treatment response and duration of response after infusion. PD, progressive disease. **e**, PET-CT scans of three representative patients before and after treatment. Red arrows indicate tumour lesions.

Data Fig. 8a-f). To unravel the features of each kind of CAR-T cell, two

clusters were defined by using CD8<sup>+</sup> memory and dysfunction/cyto-

toxicity marker genes and the expression of a wide range of memory, dysfunction and cytotoxicity genes<sup>33-35</sup> was analysed (Extended Data

Figs. 8h-j and 9a and Supplementary Table 9). Notably, the percentage

of cells in the CD8<sup>+</sup> memory cluster was significantly higher among

cells with non-viral, gene-specific targeting (PD1-19bbz, AAVS1-19bbz),

regardless of the integration site (Fig. 4a and Extended Data Figs. 8g and

9b-e). The differences caused by the distinct production methods were further uncovered by scRNA-seq of T cells collected shortly after their

preparation (Extended Data Fig. 10). In comparison with AAVS1-19bbz

cells, interference of PD1 conferred PD1-19bbz cells with an increased

immune response capability (Fig. 4b and Extended Data Fig. 11a). Next,

we conducted scRNA-seq to delineate the properties of PD1-19bbz cells

before and after infusion using three patient samples (Extended Data

Fig. 12). In line with the preclinical data, a high proportion of the CD8<sup>+</sup>

memory cluster was detected in the infusion products (Extended Data

Fig. 13 and Supplementary Table 10). We found that multiple gene sets

iGUIDE<sup>31</sup>, an improvement of the unbiased GUIDE-seg method<sup>32</sup>, were validated by deep sequencing (Extended Data Fig. 6 and Supplementary Tables 2-4 and 8). Depletion of PHACTR1 is not expected to bring about negative consequences because PHACTR1 is not reported to be expressed in T cells. Patients were given a lymphodepleting chemotherapy regimen using combined cyclophosphamide and fludarabine, followed by one infusion of PD1-19bbz cells with a dose of  $0.56 \times 10^6$  to 2.35 × 10<sup>6</sup> cells per kg body weight (Extended Data Fig. 7a,b, Extended Data Table 1 and Supplementary Tables 5 and 6). While all patients experienced transient and reversible haematological toxicity events mainly related to the chemotherapy pretreatment, no other high-grade  $(\geq 3)$  adverse events (AEs) were found (Supplementary Table 7). Mild cytokine release syndrome (CRS) was observed in some patients, while immune effector cell-associated neurotoxicity syndrome (ICANS) did not occur (Fig. 3a and Extended Data Fig. 7e-l). PD1-19bbz cells proliferated and persisted in vivo (Fig. 3b,c and Extended Data Fig. 7m). During a median observation period of 12 months, complete remission (CR) was achieved in seven of the eight patients (87.5%), as shown by positron emission tomography and computed tomography (PET-CT) scan. Durable responses were found in five patients at the time of last follow-up, whereas disease relapse was detected in two patients at 6 months (Fig. 3d, e, Extended Data Fig. 7c, d and Extended Data Table 1). Partial remission (PR) was observed in the remaining patient (1/8); thus, the best objective response rate reached was 100% in all patients. Of note, PD1-19bbz cells were effective even at a low infusion dose and with a low percentage of CAR<sup>+</sup> cells, thereby indicating the high potency of these PD1-integrated CAR-T cells. Together, these data demonstrate that non-viral, PD1-integrated CAR-T cells have high safety and efficacy for patients with r/r B-NHL.

#### Single-cell analysis of PD1-19bbz cells

To further understand the characteristics of non-viral, *PD1*-integrated CAR-T cells, single-cell RNA sequencing (scRNA-seq) was carried out in CAR-T cells prepared in parallel by different methods (Extended

associated with immune response were enriched in the infusion products of patients with better prognosis, thus showing a potential correlation between pre-infusion T cells and the effectiveness of CAR-T cell therapy, which was in line with a recent study<sup>35</sup> (Extended Data Fig. 11b and Supplementary Tables 11 and 12). Then, we set out to understand the kinetics of gene expression in CD8<sup>+</sup>CAR<sup>+</sup> cells throughout treatment. Sustained expression of some memory genes and attenuated expression of several dysfunction and cytotoxicity genes were specifically found in CAR<sup>+</sup> cells after infusion (Fig. 4c,d, Extended Data Figs. 14 and 15 and Supplementary Table 13). In accordance with the in vitro data, gene set enrichment analysis (GSEA) showed that infused CAR<sup>+</sup> cells with attenuated PD1 expression had a higher proliferation and immune response capability in vivo (Fig. 4e, Extended Data Fig. 11c and Supplementary Tables 14 and 15). Altogether, these scRNA-seq data showed that PD1-19bbz cells have an increased number of memory T cells and enhanced anti-tumour immune functions, thus giving a mechanistic explanation for their high efficacy.



**Fig. 4** | **scRNA-seq analysis of non-viral**, *PD1*-integrated CAR-T cells. **a**, Percentages of cluster 1 (C1) and cluster 2 (C2) in two donor samples prepared by different methods. C1 and C2 were generated by clustering cells on the basis of expression of CD8<sup>+</sup> memory and dysfunction/cytotoxicity marker genes, respectively. P1, patient 1; P2, patient 2. **b**, GSEA of CD8<sup>+</sup> T cells comparing AAVS1-19bbz and PD1-19bbz cells. Enriched gene sets in PD1-19bbz cells and the normalized enrichment score (NES) are shown. **c,d**, Violin plots

showing the expression of memory (c) and dysfunction/cytotoxicity (d) genes in CD8<sup>+</sup>CAR<sup>+</sup> cells from three patients before and after infusion. Data for the sample from patient 3 taken after 28 d of treatment are not shown owing to an unreliable low CAR<sup>+</sup> cell number. D, days after infusion; IP, infusion product. e, GSEA comparing CD8<sup>+</sup>CAR<sup>+</sup>PD1<sup>+</sup> and CD8<sup>+</sup>CAR<sup>+</sup>PD1<sup>-</sup> cells from three patients after 7 or 12 d of infusion. The top six most enriched gene sets in CD8<sup>+</sup>CAR<sup>+</sup>PD1<sup>-</sup> cells and the NES are shown.

#### Discussion

CRISPR-Cas9-mediated HDR is becoming a usual method to facilitate precise integration of target sequences  $^{36-38}$ . Here we generated gene-specific integrated CAR-T cells without using virus and demonstrate the feasibility of formal large-scale production for clinical application. To our knowledge, we are the first to demonstrate the safety and efficacy of non-viral, gene-specific targeted CAR-T cells in a clinical trial. Superior safety was found for patients with r/r B-NHL by using non-viral, PD1-integrated anti-CD19 CAR-T cells, with only a low incidence of mild CRS and without occurrence of neurological toxicity. Our results are also consistent with two recently reported clinical trials<sup>39,40</sup> and, accordingly, further demonstrate the safety of CRISPR-Cas9 application in T cell therapy. On the other hand, we observed high-rate and durable CR. In particular, responses were found in two patients with high PD-L1 expression, although CD19<sup>-</sup> relapse occurred in one patient later, thereby providing support for the advantage of PD1 interference in PD1-19bbz cells. Surprisingly, despite an unexpectedly low initial dose or a simultaneously low percentage of CAR<sup>+</sup> cells caused by the early and still premature manufacturing process, CR was achieved in all three of these patients, which indicates that non-viral, PD1-targeted CAR-T cells have more potency to kill tumour cells.

Our preclinical and clinical data demonstrate that PD1-19bbz cells have high efficacy against tumour cells, which can be explained by two features. First, the scRNA-seq data showed that there is a high percentage of memory T cells among PD1-19bbz cells. Intriguingly, this characteristic existed in both types of non-viral, gene-specific integrated cells, no matter where the CAR sequence was inserted, suggesting that the electroporation method using exogenous linear dsDNA can eventually produce more memory T cells in infusion products. This superiority was supported by preclinical experiments showing that AAVS1-19bbz cells more potently eradicated Raii cells at a low infusion dose than LV-19bbz cells, and PD1-19bbz cells showed a stronger ability to eradicate tumour cells with high PD-L1 expression than LV-19bbz PD1-KO cells, although PD1 knockout was achieved in both cell types. Second. the GSEA results indicate that PD1 disruption confers PD1-19bbz cells with enhanced anti-tumour immune functions. This advantage was validated by the finding that PD1-19bbz cells more vigorously eliminated tumour cells in comparison with AAVS1-19bbz cells in mouse models. Notably, this superiority was observed even in tumour cells that had low PD-L1 expression. One possible explanation for this is that loss of PD1 could relieve the immune suppression caused by PD-L1 engagement on T cells, as reported recently<sup>41</sup>. Another is that other anti-tumour immune pathways, independent of PD-L1, were ameliorated by PD1 downregulation<sup>42-44</sup>. Moreover, given that inhibitory receptors that parallel PD1 function, such as LAG3, TIM3 and TIGIT, were still highly expressed in PD1-19bbz cells after clinical infusion, simultaneously intervening in multiple pathways holds promise to further augment the function of CAR-T cells.

In this study, we describe a new strategy to develop non-viral, gene-specific targeted CAR-T cells by CRISPR–Cas9. This technology is advanced owing to combining the advantages of both non-viral manufacturing processes and precise genome editing. As a two-in-one approach without using virus, the manufacturing procedure is simplified, with shortened preparation time, reduced production expenses and increased safety and efficacy of the CAR-T cell products.

These advantages are important, especially for the generation of gene-modified CAR-T cells where virus preparation and genome editing processes are normally both required. Furthermore, locus-specific integration augments the homogeneity of the CAR-T cells and makes it possible to exploit versatile cell products. Importantly, we show the feasible application of this technology from bench to bedside and demonstrate its high safety and efficacy in a clinical trial. Thus, we propose an innovative CAR-T technology to break through the current barriers and show the considerable potential of CRISPR–Cas9-mediated non-viral, gene-specific targeted technology in cell therapy.

#### **Online content**

Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at https://doi.org/10.1038/s41586-022-05140-y.

- 1. Larson, R. C. & Maus, M. V. Recent advances and discoveries in the mechanisms and functions of CAR-T cells. *Nat. Rev. Cancer* **21**, 145–161 (2021).
- MacKay, M. et al. The therapeutic landscape for cells engineered with chimeric antigen receptors. Nat. Biotechnol. 38, 233–244 (2020).
- June, C. H., O'Connor, R. S., Kawalekar, O. U., Ghassemi, S. & Milone, M. C. CAR-T cell immunotherapy for human cancer. Science 359, 1361–1365 (2018).
- June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 64–73 (2018).
- Labanieh, L., Majzner, R. G. & Mackall, C. L. Programming CAR-T cells to kill cancer. Nat. Biomed. Eng. 2, 377–391 (2018).
- Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705–716 (2021).
- Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. *Lancet* **398**, 314–324 (2021).
- Michieletto, D., Lusic, M., Marenduzzo, D. & Orlandini, E. Physical principles of retroviral integration in the human genome. *Nat. Commun.* 10, 575 (2019).
- Russo-Carbolante, E. M. D. et al. Integration pattern of HIV-1 based lentiviral vector carrying recombinant coagulation factor VIII in Sk-Hep and 293T cells. *Biotechnol. Lett.* 33, 23–31 (2011).
- Atianand, M. K. & Fitzgerald, K. A. Molecular basis of DNA recognition in the immune system. J. Immunol. 190, 1911–1918 (2013).
- Tao, J. L., Zhou, X. & Jiang, Z. F. cGAS–cGAMP–STING: the Three Musketeers of cytosolic DNA sensing and signaling. *Iubmb Life* 68, 858–870 (2016).
- Gandara, C., Affleck, V. & Stoll, E. A. Manufacture of third-generation lentivirus for preclinical use, with process development considerations for translation to Good Manufacturing Practice. *Hum. Gene Ther. Methods* 29, 1–15 (2018).
- Hurton, L. V. et al. Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proc. Natl Acad. Sci. USA 113, E7788–E7797 (2016).
- Kebriaei, P. et al. Phase I trials using Sleeping Beauty to generate CD19-specific CAR-T cells. J. Clin. Invest. 126, 3363–3376 (2016).
- Maiti, S. N. et al. Sleeping Beauty system to redirect T-cell specificity for human applications. J. Immunother. 36, 112–123 (2013).
- Monjezi, R. et al. Enhanced CAR-T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors. *Leukemia* 31, 186–194 (2017).
- Beatty, G. L. et al. Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial. *Gastroenterology* 155, 29–32 (2018).
- Foster, J. B. et al. Purification of mRNA encoding chimeric antigen receptor is critical for generation of a robust T-cell response. *Hum. Gene Ther.* **30**, 168–178 (2019).
- Lin, L. et al. Preclinical evaluation of CD8<sup>+</sup> anti-BCMA mRNA CAR-T cells for treatment of multiple myeloma. *Leukemia* 35, 752–763 (2021).

- Eyquem, J. et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature 543, 113–117 (2017).
- Dai, X. Y. et al. One-step generation of modular CAR-T cells with AAV-Cpf1. Nat. Methods 16, 247–254 (2019).
- 22. Sather, B. D. et al. Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. *Sci. Transl. Med.* **7**, 307ra156 (2015).
- 23. Roth, T. L. et al. Reprogramming human T cell function and specificity with non-viral genome targeting. *Nature* **559**, 405–409 (2018).
- Cherkassky, L. et al. Human CAR-T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J. Clin. Invest. 126, 3130–3144 (2016).
- John, L. B. et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. *Clin. Cancer Res.* 19, 5636–5646 (2013).
   Defendent and the state of the second second
- 26. Rafiq, S. et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat. Biotechnol. **36**, 847–856 (2018).
- 27. Ren, J. T. et al. Multiplex genome editing to generate universal CAR-T cells resistant to PD1 inhibition. *Clin. Cancer Res.* **23**, 2255–2266 (2017).
- Rupp, L. J. et al. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci. Rep. 7, 737 (2017).
- 29. Su, S. et al. CRISPR–Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients. *Sci. Rep.* **6**, 20070 (2016).
- Guo, X. et al. Disruption of PD-1 enhanced the anti-tumor activity of chimeric antigen receptor T cells against hepatocellular carcinoma. Front. Pharmacol. 9, 1118 (2018).
- Nobles, C. L. et al. iGUIDE: an improved pipeline for analyzing CRISPR cleavage specificity. *Genome Biol.* 20, 14 (2019).
- Tsai, S. Q. et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat. Biotechnol. 33, 187–197 (2015).
- van der Leun, A. M., Thommen, D. S. & Schumacher, T. N. CD8<sup>+</sup> T cell states in human cancer: insights from single-cell analysis. *Nat. Rev. Cancer* **20**, 218–232 (2020).
   Sade-Feldman, M. et al. Defining T cell states associated with spaces to a backracia.
- Sade-Feldman, M. et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell **175**, 998–1013 (2018).
- Deng, Q. et al. Characteristics of anti-CD19 CAR-T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. *Nat. Med.* 26, 1878–1887 (2020).
- Doudna, J. A. The promise and challenge of therapeutic genome editing. Nature 578, 229–236 (2020).
- Hsu, P. D., Lander, E. S. & Zhang, F. Development and applications of CRISPR-Cas9 for genome engineering. Cell 157, 1262–1278 (2014).
- Komor, A. C., Badran, A. H. & Liu, D. R. CRISPR-based technologies for the manipulation of eukaryotic genomes. Cell 168, 20–36 (2017).
- Lu, Y. et al. Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. Nat. Med. 26, 732–740 (2020).
- Stadtmauer, E. A. et al. CRISPR-engineered T cells in patients with refractory cancer. Science 367, eaba7365 (2020).
- Diskin, B. et al. PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer. *Nat. Immunol.* 21, 442–454 (2020).
- Thommen, D. S. et al. A transcriptionally and functionally distinct PD-1<sup>+</sup> CD8<sup>+</sup> T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. *Nat. Med.* 24, 994–1004 (2018).
- 43. Yi, M. et al. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. *Mol. Cancer* **21**, 28 (2022).
- Patsoukis, N., Wang, Q., Strauss, L. & Boussiotis, V. A. Revisiting the PD-1 pathway. Sci. Adv. 6, eabd2712 (2020).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate

credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022

#### Methods

#### Clinical trial information and design

This study was a phase 1, open-label, single-arm clinical trial designed to evaluate the safety and efficacy of non-viral, PD1-integrated anti-CD19 CAR-T cells in treating aggressive r/r B-NHL. The clinical protocol has been registered at ClinicalTrials.gov (NCT04213469). The inclusion criteria were as follows: (1) age of 18 to 70 years; (2) diagnosis with CD19<sup>+</sup> r/r B-NHL (stages III-IV); (3) life expectancy of >3 months; (4) Eastern Cooperative Oncology Group (ECOG) score of  $\leq 2$  and satisfactory major organ functions; and (5) a negative pregnancy test for women of reproductive potential and agreement to use birth control during the study. The exclusion criteria included (1) pregnancy or breast feeding; (2) refusal to use birth control during the next 2 years: (3) allo-haematopoietic stem cell transplantation within 6 months or previous treatment of graft-versus-host disease; (4) active autoimmune disease requiring immunosuppressive agents; (5) active infection; (6) history of other malignancies; and (7) ineligibility or lack of ability to comply with the study. To preliminarily assess the safety and effectiveness of this new CAR-T cell therapy, eight patients who had not previously been treated with CAR-T cell therapy were enrolled in the cohort with an infusion dose of  $2 \times 10^{6}$  CAR-T cells per kg. Because of the premature manufacturing process and individual variance, the cell number for three infusion products could not meet the planned dose requirement; thus, the actual infusion doses in these patients were lower than  $1 \times 10^6$  cells per kg (Extended Data Table 1 and Supplementary Table 5). This therapy included 3 d of lymphodepletion chemotherapy using combined fludarabine (25 mg m<sup>-2</sup> from days -4 to -2) and cyclophosphamide (250 mg m<sup>-2</sup> from days -3 to -2). CAR-T cell infusion was performed 2 d after the end of lymphodepletion chemotherapy and was followed by standard monitoring. The trial was approved by the institutional review board, and all patients provided written informed consent in accordance with the Declaration of Helsinki before enrolment. The clinical protocol was reviewed and approved by the Clinical Research Ethics Committee of the First Affiliated Hospital, College of Medicine, Zhejiang University (2020IIT(85)). Characteristics, clinical responses and prior therapies of the patients are shown in Extended Data Table 1 and Supplementary Table 6.

#### **Response assessment**

Treatment response was assessed according to revised criteria of the Lugano classification. PET-CT scans and bone marrow biopsy were the major methods applied to evaluate lymphoma lesions. The response assessment criteria were as follows: (1) CR (complete remission): absence of clinical symptoms and PET-CT and bone marrow evidence associated with lymphoma; (2) PR (partial remission): lymphoma volume decrease of at least 50% without new lymphoma lesions or sustained bone marrow involvement; (3) PD (progressive disease): lymphoma volume increase of at least 50% or onset of new lymphoma lesions; (4) SD (stable disease): a condition that did not meet the criteria for CR, PR or PD. Response duration was calculated from the first documentation of response until disease progression, initiation of off-study treatment or the last documentation of ongoing response.

#### Assessment and grading of CRS

Serum cytokines including IL-2, IL-4, IL-6, IL-10, IFN $\gamma$ , TNF $\alpha$  and IL-17A were assessed with the Human Th1/Th2/Th17 CBA kit (BD Biosciences) within 1 month of infusion. CRS was assessed and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0 in combination with other methods<sup>45</sup>. Among the eight patients, only patient 6 was treated with an IL-6 antagonist, tocilizumab.

#### Assessment and grading of neurological toxicity

Neurological toxicities were assessed and graded according to NCI-CTCAE version 5.0. Once CRS symptoms such as pyrexia,

hypotension and capillary leak or other types of AEs were observed, the patient would be closely monitored for signs of neurological toxicity, such as seizure, tremor, encephalopathy or dysphasia.

#### Assessment and grading of AEs

Patients were inpatients and were closely monitored after receiving lymphodepletion chemotherapy and CAR-T cell infusion. Physical and clinical laboratory examinations were documented during hospitalization to evaluate the toxicity of the treatment. AEs were graded using NCI-CTCAE version 5.0. All AEs are summarized in Supplementary Table 7. During hospitalization, any AEs that occurred after CAR-T cell infusion were recorded. Severe AEs, except a decrease in lymphocyte counts caused by lymphodepletion chemotherapy, were required to be reported to the Medical Ethics Committee of the First Affiliated Hospital, College of Medicine, Zhejiang University within 24 h of occurrence. One month after infusion, patients underwent follow-up and were monitored for disease progression and toxicity once a month thereafter.

#### Immunohistochemistry

Immunohistochemistry (IHC) analysis was undertaken on formalin-fixed, paraffin-embedded tissue sections. In brief, after sections were deparaffinized in xylene and rehydrated in a graded alcohol series, endogenous peroxidase was blocked with 3% hydrogen peroxide. Antigen retrieval was performed using EDTA buffer (pH 9.0). After rinsing sections in PBS, antibodies against human CD19 (Biolynx) and PD-L1 (Agilent) were used for IHC staining. Staining was carried out on an automated immunostainer (Leica Bond-III, Dako Autostainer Link 48) using a Bond Polymer Refine Detection system.

#### **Cell lines**

293T and Nalm-6 cells were purchased from the American Type Culture Collection, and Raji cells were purchased from the Cell Bank of the Chinese Academy of Sciences. All cell lines were authenticated by short-tandem-repeat profiling. 293T cells were maintained in DMEM (Gibco) supplemented with 10% FBS (Thermo Fisher). Nalm-6 and Raji cells were maintained in RPMI-1640 (Thermo Fisher) supplemented with 10% FBS (Thermo Fisher). A Raji cell line stably expressing firefly luciferase (ffLuc) was established by lentiviral infection. Raji cells stably expressing PD-L1 were generated using a lentiviral vector containing a co-expression cassette for PD-L1 and ffLuc. All stable cell lines underwent selection with puromycin. All cell lines were regularly tested to ensure they were free of mycoplasma contamination.

#### Isolation and expansion of human primary T cells

Fresh peripheral blood mononuclear cells (PBMCs) from healthy donors were provided by the First Affiliated Hospital, College of Medicine, Zhejiang University and Shanghai SAILY Biological Technology Co., Ltd. Recruitments of healthy human blood donors was approved by the Clinical Research Ethics Committee of the First Affiliated Hospital, College of Medicine, Zhejiang University and by Shanghai Zhaxin Traditional Chinese Ethics Committee and Western Medicine Hospital. All donors signed an informed consent form. Fresh PBMCs from patients were collected by apheresis. PBMCs were isolated by density gradient centrifugation using Ficoll (Sigma-Aldrich). T cells were enriched through magnetic separation using anti-CD4 and anti-CD8 microbeads (Miltenyi Biotec) and activated with T Cell TransAct (Miltenyi Biotec). T cells were cultured in X-VIVO 15 medium (Lonza) supplemented with 2% human AB serum or CTS Immune Cell Serum Replacement (Thermo Fisher) and recombinant human IL-2 (100 U ml<sup>-1</sup>), IL-7 (5 ng ml<sup>-1</sup>) and IL-15 (5 ng ml<sup>-1</sup>). Cells were collected once cell number reached the requirement for administration and then washed, formulated and cryopreserved.

#### **Construction of CAR cassette**

The anti-CD19 CAR cassette was composed of the single-chain variable fragment derived from clone FMC63, the extracellular domain and

transmembrane regions of CD8 $\alpha$ , the intracellular domain of 4-1BB (CD137) and the intracellular domain of CD3 $\zeta$ . Transcription of the CAR element was driven by an EF1 $\alpha$  promoter and terminated by an SV40 poly(A) signal sequence. In this study, the same anti-CD19 CAR cassette was used in different constructs.

#### **Ribonucleoprotein and linear dsDNA production**

A two-component sgRNA was chemically synthesized (GenScript) and resuspended with TE buffer. Ribonucleoproteins (RNPs) were produced by complexing one sgRNA and recombinant spCas9 (Thermo Fisher) for 10 min at room temperature. RNPs were subjected to electroporation immediately after complex formation. For linear dsDNA production in preclinical experiments, plasmids containing an mTurquoise2 or anti-CD19 CAR sequence flanked by homology arms were first constructed. Linear dsDNA was then obtained by restriction endonuclease digestion and purified by TIANgel DNA Purification kit (Tiangen Biotech). The sgRNAs used were as follows: AAVS1 sgRNA (5'-AGAGCUAGCACAGACUAGAG-3'; chr19:55115996, intron 1 of PPP1R12C), PD1 sgRNA (site 1) used for the preparation of PD1-19bbz and LV-19bbz\_PD1-KO cells (5'- CGACUGGCCAGGGCGCCUGU-3'; chr2:241858824, exon 1 of PD1), PD1 sgRNA (site 2) (5'-GGGCGGUGCUACAACUGGGC-3'; chr2:241858788, exon 1 of PD1), TRAC sgRNA (5'-AGAGCAACAGTGCTGTGGCC-3'; chr14:22547693, exon 1 of TRAC), B2M sgRNA (5'-GAGTAGCGCGAGCACAGCTA-3'; chr15:44711569, exon 1 of B2M).

#### Human primary T cell electroporation

Electroporation was performed 2–3 d after T cell stimulation. For preparation of non-viral, gene-specific targeted CAR-T cells from healthy donors and some patients, the procedure was conducted following the manufacturer's instructions using a Lonza 4D electroporation system. In brief,  $2.5 \times 10^6$  to  $1.5 \times 10^7$  prewashed T cells were resuspended in 100 µl electroporation buffer P3. Meanwhile, RNPs were prepared, followed by mixture with the DNA template (1.5-20 µg). Cells in electroporation buffer were then added and moved into electroporation cuvettes. Programme EO115 was chosen for electroporation. After electroporation, cells were immediately supplemented with prewarmed medium and transferred out of the electroporation cuvettes.

To prepare PD1-19bbz cells for some patients, we followed the manufacturer's instructions using the GT Flow Transfection System (MaxCyte). In brief, prewashed T cells were resuspended in MaxCyte electroporation buffer. Meanwhile, RNPs were prepared, followed by mixture with the DNA template. Cells in electroporation buffer were then added and moved into a static processing assembly (CL-1.1). After electroporation, cells were transferred for recovery and then added to culture medium. The reaction conditions were scaled up according to those used in the Lonza 4D electroporation system.

#### CAR-T cell generation by lentivirus

The CAR sequence was cloned into the pCDH lentiviral vector backbone containing an EF1 $\alpha$  promoter. Lentivirus was produced by transfecting 293T cells with CAR plasmid, pMD2.G and psPAX2 using polyethyl-enimine. Virus-containing supernatants were collected after 3 d to infect primary human T cells stimulated for 2–3 d. LV-19bbz\_PD1-KO cells were prepared by lentiviral infection followed by electroporation using recombinant spCas9 (Thermo Fisher) and PD1 sgRNA after 2 d.

#### Indel percentage analysis

Genomic DNA was obtained using a Genomic DNA Purification kit (Thermo Fisher). Fragments containing indel sites were amplified by PCR using specific primers and purified by TIANgel DNA Purification kit (Tiangen Biotech). DNA sequencing was carried out, and the indel percentage was measured by ICE analysis (Synthego). The primers used were as follows: AAVS1-Forward, 5'-CACCACGTGATGTCCTCTGA-3'; AAVS1-Reverse, 5'-CCGGCCCTGGGAATATAAGG-3'; PD1-Forward, 5'-CCACGTGGATGTGGAGGAAG-3'; PD1-Reverse, 5'-CCACACAGCTCAGGGTAAGG-3'.

#### Genotyping of PD1-19bbz cells

PD1-19bbz cells were prepared using T cells from two independent healthy donors. Some CAR<sup>+</sup> cells were sorted by fluorescence-activated cell sorting (FACS). Genomic DNA was isolated using the Genomic DNA Purification kit (Thermo Fisher). Semiquantitative PCR using three primers in one reaction was carried out. One forward primer (5'-CCCTGCAACTGATGGTGACT-3') specifically binds to the anti-CD19 CAR cassette. A reverse primer (5'-TCACAGTGTACACAGAGGGC-3') recognizes a genomic sequence outside the right homology arm. Another forward primer (5'-GACAGTTTCCCTTCCGCTCA-3') recognizes a genomic sequence within the left homology arm. The intensity ratio of wild-type/indel and CAR-specific bands in unsorted and sorted cells was calculated by densitometry quantification to genotype PD1-19bbz cells, where A was the wild-type/indel percentage in sorted cells, B was the CAR percentage in sorted cells, C was the wild-type/indel percentage in unsorted cells and D was the CAR percentage in unsorted cells. The genotype percentages in samples were calculated with the following equations: wild-type/indel (%) =  $(B \times C - A \times D)/B \times 100\%$ , heterozygous  $(\%) = 2 \times A \times D/B \times 100\%$  and homozygous  $(\%) = (B - A) \times D/B \times 100\%$ .

#### **Deep sequencing**

Deep sequencing (10,000× coverage) was carried out to detect indels at the *PD1* on-target site and 29 top-ranked off-target sites predicted by the Benchling CRISPR tool or to validate possible indels preliminarily indicated by whole-genome sequencing or off-target events at 24 top-ranked potential sites identified by iGUIDE in one representative infusion product (patient 2). Deep sequencing (50,000× coverage) was also performed to validate off-target events at the *PHACTR1* site in different infusion products. Genomic DNA from untreated T cells and infusion products was isolated using the Genomic DNA Purification kit (Thermo Fisher). Fragments containing indel sites were amplified by PCR using specific primers and subjected to sequencing on a Hi-TOM platform as described previously<sup>46</sup>. Deep sequencing was carried out by the XI'AN CyanSnow Gene Company.

#### Whole-genome sequencing

Genomic DNA from untreated T cells and the infusion product of patient 2 was extracted using the Blood & Cell Culture DNA kit (Oiagen) according to the manufacturer's instructions and subjected to library construction. Sequencing libraries were generated using the TruSeq Nano DNA HT sample preparation kit (Illumina) following the manufacturer's recommendations, and index codes were added to attribute sequences to each sample. These libraries including untreated and edited T cells were sequenced on the HiSeq platform (Illumina) with 100× coverage. BWA (Burrows-Wheeler aligner)<sup>47</sup> was used to align clean reads for each sample against the reference genome (settings: mem -t 5 -M -R). Alignment files were converted to BAM files using SAMtools<sup>48</sup> (settings: -bS-t). In addition, potential PCR duplications were removed using the sambamba command 'markdup'. If multiple read pairs had identical external coordinates, only the pair with the highest mapping quality was retained. Indels (<50 bp) were calculated and identified with MPILEUP in SAMtools<sup>48</sup> and were processed using picard-tools. To reduce the indel detection error rate, we filtered out indels for which the number of supporting reads was less than 4, the quality value (MQ) was less than 30 and QUAL was less than 20. Indels were filtered, with those near other variants and within the pseudoautosomal region (PAR) removed. Whole-genome sequencing was carried out by Novogene Co., Ltd.

We used Cas-OFFinder (http://www.rgenome.net/cas-offinder/) to predict potential off-target sites. Any sequence, followed by an NRG protospacer adjacent motif, having no more than five mismatches (a bulge penalty equals two base mismatches) with the PD1 sgRNA was screened with a total of 2,219 sites (not including those around the on-target site) identified. Indels exclusively detected in the edited sample and located around potential off-target sites were searched. No indel events were found within 15 bp upstream and downstream ( $\pm$ 15 bp) of the sites. Indel events were detected within 200 bp upstream and downstream ( $\pm$ 200 bp) of eight sites. Deep sequencing with 10,000× coverage was performed to validate these indel events.

#### iGUIDE

The locations of off-target cleavage sites were mapped using iGU-IDE<sup>31</sup>, an improvement of the GUIDE-seq method<sup>32</sup>. In brief, stimulated T cells were mixed with RNP (spCas9–PD1 sgRNA) and a protected double-stranded oligodeoxynucleotide (dsODN) and were then subjected to electroporation. Genomic DNA was isolated as described previously after 6 d of cell culture. Next, DNA was cleaved by sonication, adaptors were ligated to free DNA ends and PCR was performed using primers that annealed to the adaptor and dsODN. PCR products were analysed by Illumina sequencing, and reads were mapped to the human genome. Given the presence of a flanking reporter dsODN sequence in correct priming, reads resulting from mispriming could be identified and filtered out. The sequencing data were analysed using the iGUIDE pipeline, available at https://github.com/cnobles/iGUIDE. The gene lists used are available at http://bushmanlab.org/assets/doc/allOnco\_ Feb2017.tsv and http://bushmanlab.org/assets/doc/humanLymph.tsv.

#### scRNA-seq

Various CAR-T cells (LV-19bbz, LV-19bbz\_PD1-KO, AAVS1-19bbz, PD1-19bbz) were prepared in parallel using T cells from two patients (patients 1 and 2) by different methods and then collected after 9 d. Several CAR-T cell types (LV-19bbz, AAVS1-19bbz, PD1-19bbz) were prepared in parallel using T cells from two healthy donors (D1 and D2) by different methods and immediately collected after 4 h. Fresh PBMCs from patients were collected by apheresis at the peak (day 7 or 12) and stable (day 28 or 29) stages of CAR-T cell expansion after infusion and then isolated by density gradient centrifugation using Ficoll (Sigma-Aldrich). Differently prepared CAR-T cells, infusion products and PBMCs from three patients (patients 1–3) were subjected to scRNA-seq.

scRNA-seq libraries were generated using a 10x Genomics Chromium Controller instrument and Chromium Single-Cell 3' V3.1 reagent kits (10x Genomics). In brief, cells were concentrated to 1,000 cells per µl and approximately 7,000 cells were loaded into each channel to generate single-cell Gel Bead-In-Emulsions (GEMs), resulting in mRNA barcoding of an expected 5,000 single cells for each sample. After the reverse transcription step, GEMs were broken and barcoded cDNA was purified and amplified. The amplified barcoded cDNA was fragmented, A-tailed, ligated with adaptors and amplified by index PCR. The final libraries were quantified using the Qubit High-Sensitivity DNA assay (Thermo Fisher), and the size distribution of the libraries was determined using a High-Sensitivity DNA chip on a Bioanalyzer 2200 (Agilent). All libraries were sequenced on an Illumina sequencer using a 150-bp paired-end run.

We applied fastp<sup>49</sup> with default parameter to filter out the adaptor sequence and remove low-quality reads to achieve clean data. Feature-barcode matrices were then obtained by aligning reads to the human genome (GRCh38 version 91, Ensembl) using CellRanger v3.1.0. We applied downsampled analysis among the samples sequenced according to the mapped barcoded reads for each cell of each sample to achieve the aggregated matrix. Cells with over 200 expressed genes and a mitochondrial unique molecular identifier (UMI) rate below 20% passed the cell quality filtering, and mitochondrial genes were removed from the expression table.

The Seurat package (v.3.1.4; https://satijalab.org/seurat/) was used for cell normalization and regression based on the expression table according to the UMI counts of each sample and the mitochondrial rate to obtain scaled data. Principal-component analysis (PCA) was performed on the basis of the scaled data with the top 2,000 most highly variable genes and the top ten principal components used for *t*-SNE construction and UMAP construction. Using the graph-based cluster method, we acquired the unsupervised cell cluster result on the basis of the top ten principal components from PCA and calculated the marker genes by the FindAllMarkers function with the Wilcoxon rank-sum test algorithm under the following criteria: (1) ln(fold change) > 0.25; (2) P < 0.05; (3) min.pct > 0.1. To characterize the relative activation of a given gene set such as the KEGG pathway 'memory, dysfunction and cytotoxicity' as described previously, we used QuSAGE (v.2.16.1)<sup>50</sup> to calculate the score for each cluster/sample and GSVA (v.1.32.0)<sup>51</sup> to calculate the score for each cell. GSEA (http://broadinstitute.org/gsea) was used to analyse differentially enriched gene sets between samples. scRNA-seq and data analysis were performed by NovelBio Bio-Pharm Technology Co., Ltd.

#### **Flow cytometry**

CAR and membrane protein expression was determined by flow cytometry. Cells were prewashed and incubated with antibodies for 30 min on ice. After washing twice, samples were run on an LSRFortessa (BD Biosciences) or DxFLEX Flow Cytometer (Beckman Coulter) and analysed with FlowJo software. The following antibodies were used: FITC anti-human CD3, APC anti-human CD69, APC anti-human CD137, APC anti-human CD25, APC anti-human PD1, APC anti-human LAG3, APC anti-human TIM3, BV421 anti-human CD45RO, APC anti-human CD62L, APC anti-human CD3, FITC anti-human CD19, FITC anti-human CD4, APC anti-human CD4, APC anti-human CD8, BV421 anti-human CD45 (all from BioLegend), PerCP-Cy5.5 anti-human CD4, BV421 anti-human CD8, PerCP-Cy5.5 anti-human CD45 (all from BD Biosciences) and APC anti-human PD-L1 (Thermo Fisher). For detection of CAR expression, biotinylated human CD19 (amino acids 20-291; ACRO Biosystems) and PE streptavidin (Bio-Legend) were added sequentially or PE-labelled human CD19 (amino acids 20-291; ACRO Biosystems) was used. For some experiments, CAR-T cells were co-cultured with target cells at an effector/target ratio of 1:1 (Raji cells) or 1:2 (PD-L1-expressing Raji cells) for 24 h before collection. For detection in clinical samples, peripheral blood cells were stained with antibodies, followed by addition of Lysis Buffer (BD Biosciences) before being run. The percentage of CAR<sup>+</sup> cells was analysed in CD45<sup>+</sup>CD3<sup>+</sup> gated cells.

#### CAR copy number analysis by qPCR

Blood samples were collected before and after CAR-T cell infusion. Lysis Buffer (BD Biosciences) was added, and genomic DNA was acquired using the Genomic DNA Purification kit (Thermo Fisher). A seven-point standard curve was generated by using  $5 \times 10^{\circ}$  to  $5 \times 10^{\circ}$  copies per µl of lentiviral vector DNA containing the 19bbz sequence. TaqMan qPCR assays were performed to measure CAR copy number in peripheral blood cells. qPCR was run on a QuantStudio 3 Real-Time PCR System (Thermo Fisher). Each sample was analysed in triplicate. Primers specifically targeting the 19bbz sequence were as follows: forward, 5'-GCTGTAGCTGCCGATTTCCA-3'; reverse, 5'-GGTTCTGGCCCTGCTTGTAC-3'; probe, 5'-AGTGAAGTTCAGCAGGAGCGCAGACG-3'.

#### Antigen stimulation and proliferation of CAR-T cells

As antigen for stimulation, Raji or PD-L1-expressing Raji cells were pretreated with mitomycin C (50  $\mu$ g ml<sup>-1</sup>) for 90 min at 37 °C. CAR-T cells were co-cultured with target cells at an effector/target ratio of 1:1 (Raji cells) or 1:2 (PD-L1-expressing Raji cells) for 3–4 d per stimulation. The number of CAR<sup>+</sup> cells was determined by multiplying the total viable cell number and the percentage of CAR<sup>+</sup> cells. Cell viability was measured by Trypan blue staining.

#### **CellTrace Violet proliferation assays**

AAVS1-19bbz cells were labelled with CellTrace Violet (Thermo Fisher) according to the manufacturer's instructions. Raji cells were pretreated with mitomycin C ( $50 \mu g m l^{-1}$ ) for 90 min at 37 °C. CAR-T cells and target

cells were mixed at an effector/target ratio of 1:1. After 5 d, cells were collected and run on an LSRFortessa (BD Biosciences).

#### **Bead-based immunoassays**

In preclinical experiments, CAR-T cells were co-cultured with Raji or PD-L1-expressing Raji cells at an effector/target ratio of 1:1 (Raji cells) or 1:2 (PD-L1-expressing Raji cells) in medium without exogenous cytokines. The supernatant was collected after 24 h, and cytokines were measured using LEGENDplex bead-based immunoassays (Bio-Legend) according to the manufacturer's instructions.

#### ELISAs

For in vitro evaluation of infusion products, CAR-T cells were co-cultured with Nalm-6 cells at an effector/target ratio of 1:1 in medium without exogenous cytokines. The supernatant was collected after 18-24 h, and IFN $\gamma$  secretion was measured using the Human IFN- $\gamma$  ELISA kit (StemCell) according to the manufacturer's instructions.

#### Flow cytometry-based cytotoxicity assays

AAVS1-19bbz cells were co-cultured with Raji cells at an effector/target ratio of 1:1 for 18 h. Flow cytometry was used to detect residual tumour cells by staining with APC anti-human CD3 and FITC anti-human CD19 antibodies. Cells were enumerated using CountBright Absolute Counting Beads (Thermo Fisher) following the manufacturer's instructions.

#### LDH cytotoxicity assays

CAR-T cells were co-cultured with Nalm-6, Raji or PD-L1-expressing Raji cells at the indicated effector/target ratios. Cytotoxicity was measured by release of LDH using the CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega) according to the manufacturer's instructions.

#### In vivo mouse experiments

All animal experiments were conducted in compliance with the Guide for the Care and Use of Laboratory Animals (2011) issued by the National Research Council (USA), Laboratory Animal Administration Regulation (2017) issued by the National Science and Technology Committee (China) and the laboratory animal administration regulations (Shanghai, Jiangsu). The care and use of animals were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of the East China Normal University Center for Animal Research or InnoStar Bio-tech Nantong Co., Ltd. For the experiment comparing the LV-19bbz and AAVS1-19bbz groups at a high infusion dose, 6- to 8-week-old B-NDG (NOD.CB17-*Prkdc<sup>scid</sup>ll2rg<sup>tm1</sup>*/Bcgen) male mice (Biocytogen) were injected intravenously with  $2 \times 10^5$  ffLuc-transduced Raji cells. Subsequently,  $2 \times 10^{6}$  CAR-T cells were administered intravenously after 5 d. For the experiment comparing the LV-19bbz, AAVS1-19bbz and PD1-19bbz groups at a low infusion dose, 6- to 9-week-old NCG (NOD/ ShiLtJGpt-*Prkdc*<sup>em26Cd52</sup>*Il2rg*<sup>em26Cd22</sup>/Gpt) female mice (GemPharmatech) were injected intravenously with  $2 \times 10^5$  ffLuc-transduced Raji cells. Subsequently,  $1 \times 10^{6}$  CAR-T cells were administered intravenously after 5 d. For other experiments, 6- to 9-week-old NCG female mice (GemPharmatech) were inoculated intravenously with  $5 \times 10^{5}$  ffLuc-transduced PD-L1-expressing Raji cells. Subsequently, 1 × 10<sup>6</sup> or 2 × 10<sup>6</sup> CAR-T cells were injected intravenously after 5 d. Bioluminescence images were acquired and analysed using the IVIS Imaging System and software (PerkinElmer). Mice were randomized on the basis of tumour radiance before CAR-T cell injection. Mice were killed according to the experimental protocols or when they met prespecified endpoints defined by the IACUC. Animal technicians were blinded to expected outcomes. The experiments were performed in the East China Normal University Center for Animal Research or InnoStar Bio-tech Nantong Co., Ltd.

#### Statistics

Experimental data are presented as the mean  $\pm$  s.d. or the mean  $\pm$  s.e.m. as described in the figure legends. Data were analysed by one-way ANOVA, two-way ANOVA or log-rank Mantel–Cox test as indicated using GraphPad software. *P* < 0.05 was considered statistically significant. Asterisks are used to indicate significance: \*\*\*\**P* < 0.0001, \*\*\**P* < 0.001, \*\**P* < 0.05. NS, not significant.

#### **Reporting summary**

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

#### **Data availability**

scRNA-seq data have been deposited in the GEO database (GSE166352, GSE186596, GSE201035). Whole-genome sequencing, iGUIDE and deep sequencing data have been deposited in the SRA database (PRJNA774073, PRJNA772163, PRJNA772700, PRJNA772894, PRJNA772887, PRJNA772893). Source data are provided with this paper.

- Lee, D. W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. *Blood* 124, 188–195 (2014).
- Liu, Q. et al. Hi-TOM: a platform for high-throughput tracking of mutations induced by CRISPR/Cas systems. Sci. China Life Sci. 62, 1–7 (2019).
- 47. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows–Wheeler transform. *Bioinformatics* **25**, 1754–1760 (2009).
- Li, H. et al. The Sequence Alignment/Map format and SAMtools. *Bioinformatics* 25, 2078–2079 (2009).
- Chen, S. F., Zhou, Y. Q., Chen, Y. R. & Gu, J. fastp: an ultra-fast all-in-one FASTQ preprocessor. *Bioinformatics* 34, 884–890 (2018).
- Yaari, G., Bolen, C. R., Thakar, J. & Kleinstein, S. H. Quantitative set analysis for gene expression: a method to quantify gene set differential expression including gene–gene correlations. *Nucleic Acids Res.* **41**, e170 (2013).
- Hanzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-Seq data. BMC Bioinf. 14, 7 (2013).

Acknowledgements We thank S. Siwko for discussing and revising this manuscript. This study was supported by the National Key R&D Program of China (2019YFA0802802, 2018YFA0507001), the National Natural Science Foundation of China (81772622, 81730008, 81770201, 91857116, 31871453), the Innovation Program of the Shanghai Municipal Education Commission (2017-01-07-00-05-E00011), the Key Project of the Science and Technology Department of Zhejiang Province (2019C03016) and the Natural Science Foundation of Shanghai (18ZR1412300). It was also supported by the ECNU Public Platform for Innovation (011) and the Instruments Sharing Platform of the Science, East China Normal University.

Author contributions J.Z., Y.H., Dali Li, B.D., M.L. and H.H. designed the overall study and wrote the manuscript. Y.H., W.L. and H.H. designed the clinical trial. J.Z., J.Y., L.Z., Y.T., A.C. and Y.Q. performed the experiments. J.Z., Q.W., B.T. and Deqi Li were responsible for manufacturing and quality control of CAR-T cells for treatment. Y.H., M.Z., G.W., K.Z., J.C. and Y.L. performed the clinical trial. J.Z., Y.H. and W.L. analysed the data. D.W. and Y.W. discussed the results and manuscript. J.Z., Dali Li, B.D., M.L. and H.H. supervised the study. All authors approved the manuscript for submission and publication.

**Competing interests** This study was partially supported by BRL Medicine, Inc. Patent applications related to this manuscript have been submitted (J.Z., J.Y., Y.T., B.D., Dali Li, M.L., Z.X. 'sgRNA guiding *PD*1 gene for cleavage to achieve efficient integration of exogenous sequences'; J.Z., B.D., M.L., Z.X. 'Method for performing gene editing on target site in cell').

#### Additional information

 $\label{eq:supplementary} Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41586-022-05140-y.$ 

**Correspondence and requests for materials** should be addressed to Jiqin Zhang, Dali Li, Bing Du, Mingyao Liu or He Huang.

Peer review information Nature thanks Justin Eyquem, Norihiro Watanabe and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Reprints and permissions information is available at http://www.nature.com/reprints.



Extended Data Fig. 1| Optimization of the conditions for producing non-viral gene-specific targeted T cells. a-j, The sequence of the fluorescent protein mTurquoise2 was used as a target to optimize the conditions for generating non-viral gene-specific integrated T cells. a, Number of viable cells calculated 7 days after electroporation by using different protocols. Equal quantities of circular plasmid DNA and linear double-stranded DNA (dsDNA) were used. Due to acquisition of higher cell viability, templates in the form of linear dsDNA were chosen for all the following experiments. b-c, Homologous recombination efficiency of mTurquoise2 at two PD1 sites (b) and one AAVS1 site (c) by using different DNA templates. HDR, homology directed repair. HITI, homology-independent targeted integration. HITI (pb), HITI template with 50bp protection base pairs flanking the target sequence. MMEJ, microhomology-mediated end joining. d, Homologous recombination efficiency of mTurquoise2 using 33bp or 800bp homology arms. Equal mole or quantity of template harboring 33bp homology arms was used, compared with template with 800bp homology arms. e, Homologous recombination efficiency of mTurquoise2 by using unmodified or modified DNA templates with 200bp homology arms. PS, phosphorothioate. Biotin was modified at the





f





first base pair from the 5' side. PS was modified at the first three or five base pairs from the 5' side. f, Homologous recombination efficiency of mTurquoise2 in unstimulated or stimulated T cells using different electroporation programs and DNA templates.g, Homologous recombination efficiency of mTurquoise2 in fresh or recovered T cells after stimulation for indicated days by using HDR templates with 800bp homology arms. h-j, Homologous recombination efficiency (h) and numbers of all viable cells (i) and viable mTurquoise2+ cells (j) were detected using mTurquoise2 templates with different homology arm lengths.k, Number of all viable cells was enumerated using CAR templates with different homology arm lengths. 800bp and 20bp homology arms were used in HDR and MMEJ templates, respectively (a-c, f). Equal moles of DNA template were used in b, c, e-k. The homologous recombination efficiency was determined 7 days after electroporation in b-k. All the experiments were performed in cells from two independent healthy donors. Mean value is shown in all the figures. P values were calculated by one-way ANOVA with Tukey's multiple comparisons test (g) or two-way ANOVA with Tukey's multiple comparisons test (e).



Extended Data Fig. 2 | See next page for caption.

Extended Data Fig. 2 | Comparison of non-viral gene-specific integrated CAR-T cells and lentivirus-produced CAR-T cells. a, Percentages of CAR integration and AAVS1 indels in total T cells were detected 7 days after electroporation in five representative healthy donors. b, Cell viability detected by trypan blue staining on indicated days post infection/electroporation. Data are mean ± SEM (n = 3 independent healthy donors). c-d, Absolute (c) and relative (d) rates of T cell growth in vitro (n = 3 independent healthy donors). Data are mean ± SEM in c. e, Representative histogram showing Cell Trace Violet staining of T cells after co-culture with mitomycin C-treated Raji cells for 5 days. This experiment was repeated at least three times using different donors. f-g, In vitro cytotoxicity against Raji cells determined by flow cytometry. f, Representative plots showing lysis of Raji cells following 18 h co-culture.g, The percentage of Raji tumor cell death detected by flow cytometry-based cytotoxicity assay (n = 3 independent healthy donors). h, Bioluminescence kinetics of tumor cell growth following different treatments (n = 5). Immunodeficient mice were injected intravenously with 2×10<sup>5</sup> ffLuc-transduced Raji cells and 2×10<sup>6</sup> CAR-T cells were administered intravenously after 5 days, i. Kaplan-Meier analysis of survival of mice in h. j, Percentages of CAR+ cells in CD4+ and CD8+ cells determined 3 or 6 days after infection/electroporation. Data are mean  $\pm$  SEM (n = 4 independent healthy donors). k, Ratio of CD4+ and CD8+ cells on indicated days post infection/ electroporation. Data are mean  $\pm$  SEM (n = 3 independent healthy donors). l, MFI of CD69, CD137 and CD25 expression in T cells detected by flow cytometry after 24 h co-culture with PD-L1 expressing Raji cells (n = 3 independent healthy

donors). m, For the samples of AAVS1-19bbz and PD1-19bbz, CAR+ cells were sorted by fluorescence-activated cell sorting (FACS). Genomic DNA was used as template to amplify PCR products across the homology arms. Sanger sequencing was performed from end to end, outside of homology arms. n-o, Sequences of 5' and 3' junction sites between the homology arm and CAR cassette at the AAVS1 (n) and PD1 (o) locus. p, Genotyping of PD1-19bbz cells in two independent healthy donors by calculating the intensity ratio of WT/indel and CAR specific bands in unsorted and sorted CAR+ cells. WT, wild type. q, Non-specific integration of CAR elements was tested 7 days after electroporation by using recombinant spCas9 and different combinations of DNA template and sgRNA (n = 2 independent healthy donors). For the groups of AAVS1, PD1 and TRAC templates, one B2M sgRNA with high cleavage efficiency was used as off-target sgRNA. For the B2M template group, one TRAC sgRNA with high cleavage efficiency was used as off-target sgRNA. The off-target groups were designed to detect non-targeted integration under a hypothesized condition that sgRNA had very high off-target cleavage efficiency. r, PD-L1 expression in Raji cell lines. Control samples were electroporated the same as AAVS1-19bbz or PD1-19bbz cells except without sgRNA addition. CD3+ (Untreated T, Control) or CD3+/CAR+ (LV-19bbz, AAVS1-19bbz, PD1-19bbz) gated cells were analysed in e, l. Mean value is shown in d, g, l, q. P values were calculated by one-way ANOVA with Tukey's multiple comparisons test (g, l), two-way ANOVA with Tukey's multiple comparisons test (b, d) and Sidak's multiple comparisons test (j) or log-rank Mantel-Cox test (i).



Extended Data Fig. 3 | Non-viral gene-specific integrated CAR-T cells exhibit similar antigen-independent and -dependent tonic signalling as lentivirus-produced CAR-T cells. a, MFI of CAR expression in T cells detected by flow cytometry without antigen stimulation (n = 6 independent healthy donors). b, Percentages of PD1 expression in CD4+/CAR+ and CD8+/CAR+ cells detected by flow cytometry without antigen stimulation. c-g, MFI of CD69, CD137, CD25, LAG3 and TIM3 expression in CD4+/CAR+ and CD8+/CAR+ cells

without antigen stimulation. h, Percentages of PD1 expression in CD4+/CAR+ and CD8+/CAR+ cells after 24 h co-culture with Raji cells. i-m, MF1 of CD69, CD137, CD25, LAG3 and TIM3 expression in CD4+/CAR+ and CD8+/CAR+ cells after 24 h co-culture with Raji cells. The experiments were performed in three independent healthy donors (b-m). Mean value is shown in all the figures. P values were calculated by one-way ANOVA with Tukey's multiple comparisons test (a, c-g, i-m).



Extended Data Fig. 4 | Non-viral PD1-integrated CAR-T cells effectively eradicate tumor cells with either high or low PD-L1 expression at a low or high infusion dose. a-e, Immunodeficient mice were injected intravenously with  $5 \times 10^5$  ffLuc-transduced PD-L1 expressing Raji cells and  $1 \times 10^6$  CAR-T cells were administered intravenously after 5 days. a, Bioluminescence kinetics of tumor cell growth in each treatment group (n = 4 or 8). b-d, Percentages of PD1, LAG3 and TIM3 expression in peripheral CAR-T cells detected 7 days after CAR-T cell infusion. Data are mean ± SEM (n = 3). e, After CAR-T cell infusion for 7 days, the T cell subset differentiation in peripheral CAR-T cells was analysed according to CD45RO/CD62L expression by flow cytometry. Data are mean ± SEM (n=3). f-i, Immunodeficient mice were injected intravenously with 5×10<sup>5</sup> ffLuc-transduced PD-L1 expressing Raji cells and 2 × 10<sup>6</sup> CAR-T cells were administered intravenously after 5 days. The T cells were harvested from the same healthy donor as that in Fig. 2h-j and a-e. f-h, Bioluminescence imaging (f) and kinetics (g, h) of tumor cell growth following different treatments (n = 4 or 5). Data are mean ± SEM in g. i, Kaplan-Meier analysis of

survival of mice in f. j-m, Immunodeficient mice were injected intravenously with  $5 \times 10^5$  ffLuc-transduced PD-L1 expressing Raji cells and  $2 \times 10^6$  CAR-T cells were administered intravenously after 5 days. The T cells were harvested from one healthy donor who was different from that in Fig. 2h-j and a–i. j-l, Bioluminescence imaging (j) and kinetics (k, l) of tumor cell growth following different treatments (n = 4 or 6). Data are mean ± SEM in k. m, Kaplan-Meier analysis of survival of mice in j. n-q, Immunodeficient mice were injected intravenously with  $2 \times 10^5$  ffLuc-transduced Raji cells and  $1 \times 10^6$  CAR-T cells were administered intravenously after 5 days. n-p, Bioluminescence imaging (n) and kinetics (o, p) of tumor cell growth following different treatments (n = 4 or 8). Data are mean ± SEM in o. q, Kaplan-Meier analysis of survival of mice in different treatments (n = 4 or 8). Data are mean ± SEM in o. q, Kaplan-Meier analysis of survival of mice in n. The imaging on indicated days after CAR-T cell infusion and the radiance scale (p/s/cm<sup>2</sup>/sr) are shown (f, j, n). P values were calculated by one-way ANOVA with Tukey's multiple comparisons test (b-d) or log-rank Mantel-Cox test (m, q).



**Extended Data Fig. 5** | In vitro **evaluation of non-viral** *PD1***-targeted CAR-T cell products.** a, Percentage of CAR+ cells in the final products of r/r B-NHL patients (n = 8 patient donors). b, CAR expression determined in three representative patient donors. c, Gating strategy for the detection of CAR expression. d-e, Percentages of CAR integration (e) and *PD1* indels (d, e) in the final products (n = 8 patient donors). f, Cell viability of the final products

detected by trypan blue staining (n = 8 patient donors). g, IFN- $\gamma$  secretion measured by ELISA in the supernatant after co-culture with Nalm-6 cells for 18– 24 h. Data are mean ± SD (n = 3 technical replicates). h, In vitro cytotoxicity against Nalm-6 cells determined using LDH assay. E/T, effector/target. Data are mean ±SD (n = 3 technical replicates). Mean value is shown in a, d, f.



Target	Gene ID	Edit Site	Туре	Target sequence	PAM	Mismatch	Patient-2	Patient-3	Patient-4	Patient-5	Patient-6	Patient-7	Patient-8
On	PDCD1*	chr2:+:241858824 (exon 1)	Wild type	CGACTGGCCAGGGCGCCTGT	GGG	0	NA						
	PHACTR1*		Wild type	TTCATGGCCAGGGAGCCTGT	AGG	5	NA						
Off		chr6:-:13230036 (intron 9)	Mutation	TTCATGGCCAGGGAGCC-GT	NA	NA	1.39%	0.90%	1.20%	0.79%	0.60%	1.01%	0.69%
			wutation	TTCATGGCCAGGGAGC-TGT	NA	NA	0.00%	0.58%	0.00%	0.00%	0.00%	0.64%	0.00%

Extended Data Fig. 6 | Off-target detection in non-viral PD1-integrated CAR-T cell products. a, Off-target detection by whole genome sequencing (WGS) and deep sequencing. The genomic DNA of untreated T cells and the infusion product of patient-2 was subjected to 100×WGS. A total of 2,219 potential off-target sites (not including those around the on-target site) were predicted by Cas-OFFinder and compared with exclusive indels in the edited sample by bioinformatics. No indel events were detected within 15bp upstream and downstream ( $\pm 15$ bp) of the sites. Indels were found within 200bp upstream and downstream (±200bp) of eight sites. Deep sequencing (10,000× coverage) was then performed to validate these indel events. While no indels were detected at five sites, indels at the other three sites were variances of one unit length on nucleotide repeats and thus were not considered to be true off-target events. b-e, Identification of off-target sites by iGUIDE. b, Genomic distribution of oligonucleotide (dsODN) incorporation sites by bioinformatic characteristics. The ring indicates the human chromosomes aligned end-to-end, plus the mitochondrial chromosome (labeled M). The frequency of

cleavage and subsequent dsODN incorporation is shown on a log scale on each ring (pooled over 10 Mb windows). The purple inner most ring plots all alignments identified. The green ring shows three or more unique alignments that overlap with each other (pileup alignment). The blue ring shows alignments that can be found on either side of a dsODN incorporation site (flanking pairs). The red ring shows reads with matches to the gRNA (allowing < 6 mismatches) within 100 bp (target matched). c, Distance distribution of identified incorporation sites from the PD1 on-target locus. The percentage of incorporations within 100 bp of the on-target site is shown. d, Potential off-target cleavage sites identified by iGUIDE. Abund., the total number of unique alignments associated with the site. MESL, maximum edit site likelihood. Gene\_ID, an identifier indicating the nearest gene. Symbols after the gene name indicate: \* the site is within the transcription unit of the gene, ~ the gene appears on the cancer-association list. e, Deep sequencing (50,000× coverage) to validate off-target events at the PHACTR1 site in different infusion products.



Extended Data Fig. 7 | PD-L1 and CD19 expression in the tumor tissues, serum cytokine profiles and peripheral CD19+ cell percentage in the patients treated with non-viral PD1-targeted CAR-T cells. a. Representative immunohistochemistry (IHC) staining of PD-L1 protein expression in the patients' tumor tissues before treatment. b. Evaluation of PD-L1 expression level and percentage in IHC staining. c, Representative IHC staining of CD19 protein expression in the patients' tumor tissues before treatment and after disease progression or relapse. d, Evaluation of CD19 expression level and percentage in IHC staining. e-l, Serum cytokines including IL-2, IL-4, IL-6, IL-10, IFN- $\gamma$ , TNF- $\alpha$  and IL-17A were assessed in eight r/r B-NHL patients on indicated days after infusion. m, Percentage of CD19+ cells in the peripheral lymphocytes of patients on indicated months after infusion. Scale bars represent 50  $\mu$ m.



Extended Data Fig. 8 | Single-cell RNA sequencing analysis of CAR-T cells prepared by different methods. a, Overview of the 63,789 cells that passed quality control (QC) for single-cell analysis. Cells are color coded by sample, respectively, in the t-distributed stochastic neighbor embedding (tSNE) plot. b, Expression of T cell marker genes (CD3D, TRAC) in the tSNE plots. c, Cells are color coded by CD4+ and CD8+ cells in the tSNE plot. d, tSNE plots showing CD4+ and CD8+ cell clusters in each sample. e-f, CD4+ and CD8+ cell proportion in total (e), CAR+ and CAR- (f) samples. g-j, CD8+ T cells were analysed in the

samples prepared by different methods. g, Distribution of CAR+ and CAR- cells in the tSNE plot. h, tSNE plot showing two clusters in the samples. Cluster 1 (C1) and cluster 2 (C2) were generated by clustering CD8 memory and dysfunction/ cytotoxicity marker genes, respectively. i, Expression of representative CD8 memory genes (SELL, LEF1, IL7R) in the tSNE plots. j, Expression of representative CD8 dysfunction/cytotoxicity genes (LAG3, TIGIT, IFNG) in the tSNE plots.



Extended Data Fig. 9 Proportion of CD8 memory and dysfunction clusters in CAR-T cells prepared by different methods. a, Heat map showing scaled expression of memory, dysfunction and cytotoxicity genes in two CD8+T cell clusters. The gene set variation analysis (GSVA) scores of CD8 memory,

dysfunction and cytotoxicity signatures are shown at the top. b, tSNE plots showing C1 and C2 in each sample. c, Percentages of C1 and C2 in mixed samples. d-e, Comparison of C1 and C2 proportion between CAR+ and CARcells in mixed (d) and individual (e) samples.



**Extended Data Fig. 10 | Single-cell RNA sequencing analysis of T cells collected shortly after preparation by different methods.** Single-cell RNA sequencing was applied to analyse the characteristics of T cells collected 4 h after preparation by different methods. a, Overview of the 46,558 cells that passed QC for single-cell analysis. Cells are color coded by sample,

respectively, in the tSNE plot. b, Expression of T cell marker genes (CD3D, TRAC) in the tSNE plots. c-d, Metabolism (c) and other (d) pathway activities in T cells were scored using the quantitative set analysis for gene expression (QuSAGE) method.



#### Extended Data Fig. 11 | Gene set enrichment analysis of non-viral PD1-integrated CAR-T cells. a, Gene set enrichment analysis (GSEA) of CD8+ T cells comparing AAVS1-19bbz and PD1-19bbz cells. Enriched gene sets in PD1–19bbz cells and the normalized enrichment score (NES) are shown. b, GSEA of CD8+ T cells comparing the infusion products of patients with different prognosis (patient-1/patient-2, better prognosis; patient-3, worse prognosis). The top ten most enriched gene sets in patient-1/patient-2 group and the NES are shown. c, GSEA comparing different time point samples from patient-1 and patient-2 before and after infusion. CD8+ cells were analysed in the infusion

products (IP). CD8+/CAR+/PD1- (left) and CD8+/CAR+/PD1+ (right) cells were analysed in D12 and D28/D29 samples after infusion, respectively. The serial numbers and names of enriched gene sets and the NES are shown. Positive values of the NES (red) represented the enrichment of gene sets in D12 (vs. IP) and D28/D29 (vs. D12) samples. Negative values of the NES (blue) represented the enrichment of gene sets in IP (vs. D12) and D12 (vs. D28/D29) samples. The patient-3 samples were not subjected to this analysis owing to an unreliable low CAR+ cell number in D28 sample.





36,201 cells in the T/NK cell cluster. Cells are color coded by cell type in the tSNE plot. g, tSNE plots showing subtypes in the T/NK cell cluster in each sample. h, Proportion of subtypes in the T/NK cell cluster in each sample. i, Bubble heat map showing marker gene expression for different subtypes in the T/NK cell cluster.



Extended Data Fig. 13 | Proportion of CD8 memory and dysfunction clusters in infusion products. CD8+ T cells were analysed in the infusion products of three patients. a, Distribution of CAR+ and CAR- cells in the tSNE plot. b, tSNE plot showing two clusters in the infusion products. C1 and C2 were generated by clustering CD8 memory and dysfunction/cytotoxicity marker genes, respectively. c, Expression of representative CD8 memory genes (SELL, LEF1, IL7R) in the tSNE plots. d, Expression of representative CD8 dysfunction/ cytotoxicity genes (LAG3, TIGIT, IFNG) in the tSNE plots. e, Heat map showing scaled expression of memory, dysfunction and cytotoxicity genes in two CD8+ T cell clusters. The GSVA scores of CD8 memory, dysfunction and cytotoxicity signatures are shown at the top. f, Percentages of C1 and C2 in mixed and individual samples of infusion products. g, Comparison of C1 and C2 proportion between CAR+ and CAR- cells in mixed and individual samples of infusion products.



Extended Data Fig. 14 | Expression of CD8 memory and dysfunction/ cytotoxicity genes in non-viral *PD1*-targeted CAR-T cells before and after infusion. a, Heat map showing scaled expression of memory, dysfunction and cytotoxicity genes in CD8+/CAR+ cells from three patients before and after infusion. The GSVA scores of CD8 memory, dysfunction and cytotoxicity signatures are shown at the top. b,c, Violin plots showing the expression of memory and dysfunction/cytotoxicity genes in CD8+/CAR+ cells from individual (b) and mixed (c) samples of three patients before and after infusion. d, Violin plots showing the expression of memory and dysfunction/ cytotoxicity genes in CD8+/CAR+ and CD8+/CAR- cells from two patients after 28 or 29 days infusion. The data of the patient-3 sample taken after 28 days treatment is excluded from mixed samples and not shown individually owing to an unreliable low CAR+ cell number.



**Extended Data Fig. 15 | Pathway activities in non-viral PD1-integrated CAR-T cells before and after infusion.** a-b, Metabolism (a) and other (b) pathway activities were scored using the QuSAGE method in CD8<sup>+</sup>/CAR<sup>+</sup> cells from three patients before and after infusion. The data of patient-3 sample after 28 days treatment is not shown owing to an unreliable low CAR $^+$  cell number.

#### Extended Data Table 1 | Patient characteristics, clinical responses and adverse events

Patient	Sex	Age (years)	Lymphoma type	Number of prior lines of therapy <sup>a</sup>	Disease stage	Lymphoma status <sup>b</sup>	CAR+ cell dose (/kg)	Best response (duration in months) <sup>c</sup>	CRS	Neurological toxicity
Patient-1	М	44	GCB DLBCL	5	N	Refractory	0.56×10 <sup>6</sup>	CR (15+)	Grade 1	None
Patient-2	М	53	Non-GCB DLBCL	4	N	Refractory	2.04×10 <sup>6</sup>	CR (15+)	Grade 1	None
Patient-3	М	59	GCB DLBCL	3	N	Refractory	1.95×10 <sup>6</sup>	PR (1)	Grade 1	None
Patient-4	М	46	Non-GCB DLBCL	10	N	Relapsed within 6 months after ASCT	0.8×10 <sup>6</sup>	CR (5)	None	None
Patient-5	F	43	B-LBL	4	N	Refractory	0.76×10 <sup>6</sup>	CR (4)	None	None
Patient-6	F	64	Non-GCB DLBCL	4	N	Refractory	2.35×10 <sup>6</sup>	CR (11+)	Grade 2	None
Patient-7	F	62	GCB DLBCL	1	Ш	Refractory	2.15×10 <sup>6</sup>	CR (11+)	None	None
Patient-8	F	51	FL	3	N	Refractory	1.9×10 <sup>6</sup>	CR (11+)	None	None

ASCT, autologous stem cell transplantation; B-LBL, B-cell lymphoblastic lymphoma; CR, complete remission; DLBCL, diffuse large B cell lymphoma; FL, female; FL, follicular lymphoma; GCB, germinal center B cell; M, male; PR, partial remission. "All prior lines of therapy for each patient are listed in Supplementary Table 6. None of the patients were treated with CAR-T cell therapy previously. "Disease was defined as refractory if a patient did not achieve partial or complete remission after the most recent chemotherapy. "Best response was defined as the best response that a patient achieved after CAR-T cell infusion. Response duration is the time from the first documentation of response, until disease progression, initiation of off-study treatment or the last documentation of ongoing response. The + symbol indicates an ongoing response.

# nature portfolio

Corresponding author(s): He Huang

Last updated by author(s): Jul 1, 2022

# **Reporting Summary**

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

#### **Statistics**

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a	Cor	firmed
	$\boxtimes$	The exact sample size $(n)$ for each experimental group/condition, given as a discrete number and unit of measurement
	$\boxtimes$	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	$\boxtimes$	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
$\boxtimes$		A description of all covariates tested
	$\boxtimes$	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	$\boxtimes$	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	$\boxtimes$	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give <i>P</i> values as exact values whenever suitable.
$\boxtimes$		For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
$\boxtimes$		For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
$\boxtimes$		Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
		Our web collection on statistics for biologists contains articles on many of the points above.

## Software and code

Policy information about availability of computer code

Data collection Electronic Case Report Forms (eCRF) (v1.0) for clinical data. 4D-Nucleofector X Unit (Lonza) or GT Flow Transfection System (MaxCyte) for preparation of non-viral genome specific targeted (CAR) T cells. LSRFortessa (BD Biosciences) using FACSDiva software (v8.0.1) or DxFLEX Flow Cytometer (BECKMAN COULTER) using CytExpert software (v1.1.11.8) for flow cytometry analysis. FACSAria II (BD Biosciences) using FACSDiva software (v8.0.1) for FACS. NC-200 (ChemoMetec) or Countstar® BioMed (IM1200) for cell counting. SPECTROstar Nano (BMG LABTECH) using the software (v2.12) for OD detection. QuantStudio 3 Real-Time PCR System (Applied Biosystems) for qPCR. IVIS® Spectrum Imaging System (PerkinElmer) using Living Image® software (v4.5 or v4.7.3) for bioluminescence imaging. HiSeq X Ten platform (Illumina) for iGUIDE and deep sequencing. NovaSeq 6000 platform (Illumina) for WGS and scRNA-seq. Siemens Biograph16 PET/CT using Syngo VD30C SL18P60 software for PET/CT imaging. Automated immunostainer (Bond-III, Leica or Autostainer Link 48, Dako) using a Bond Polymer Refine Detection system for IHC staining.

Data analysis BWA (v0.7.8-r455), SAMtools (v1.0), Sambamba (v0.4.7), picard-tools (v1.107), ANNOVAR (version 2017June8) for WGS data analysis. CellRanger (v3.1.0), Seurat package (v3.1.4), QuSAGE (v2.16.1), GSVA (v1.32.0), GSEA (http://broadinstitute.org/gsea) for scRNA-seq data analysis. Deep sequencing was analyzed using HiTOM analysis (Liu et al, SCIENCE CHINA Life Sciences, 2019). Indel percentage was analyzed using ICE v2 CRISPR Analysis Tool (Synthego, https://www.synthego.com/products/bioinformatics/crispr-analysis). Cas-Offinder (v2.4) (http:// www.rgenome.net/cas-offinder/) or the Benchling CRISPR tool (https://www.benchling.com/) for predicting potential off-target sites. iGUIDE pipeline (https://github.com/cnobles/iGUIDE) for iGUIDE analysis. ImageJ (1.46r) for densitometry quantification. Flow cytometry data was analyzed using FlowJo (v10). GraphPad Prism (v7) was used to analyze other data.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

#### Data

#### Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

ScRNA-seq data has been deposited in GEO database (GSE166352, GSE186596, GSE201035). WGS, iGUIDE and deep sequencing data have been deposited in SRA database (PRJNA774073, PRJNA772163, PRJNA772700, PRJNA772894, PRJNA772887, PRJNA772893).

#### Human research participants

Policy information about studies involving human research participants and Sex and Gender in Research.

Reporting on sex and gender	Male and female patients were enrolled in the clinical trial and reported in this study. Sex was not especially considered, as this was a consecutive cohort study referring to other reports. The disaggregated sex data and overall numbers were provided in Results.
Population characteristics	Eight patients were enrolled to receive the infusion of PD1-19bbz cells at a planned dose of 2×10^6 CAR T cells/kg. The population characteristics of them are shown in Table 1. Their ages range from 43 to 62 years old and sex is evenly distributed. Seven patients received at least three prior lines of therapy and one patient received one prior line of therapy. The details of prior therapies are provided in Supplementary table 3. Healthy human blood donors were male or female and mostly between 18 and 28 years old.
Recruitment	Patients were recruited through public recruitment advertisement which was approved by the First Affiliated Hospital, College of Medicine, Zhejiang University or through the recommendation from the hospital's doctors according to the medical history and results of routine tests. Eight patients were enrolled based on the inclusion and exclusion criteria in this clinical trial. The trial was approved by the institutional review board and all patients provided written informed consent in accordance with the Declaration of Helsinki before enrolment. Fresh PBMCs from healthy donors were provided by the First Affiliated Hospital, College of Medicine, Zhejiang University and Shanghai SAILY Biological Technology Co., Ltd. The recruitments of healthy human blood donors were approved by the Clinical Research Ethics Committee of the First Affiliated Hospital, College of Medicine, Zhejiang University and by Shanghai Zhaxin Traditional Chinese Ethics Committee and Western Medicine Hospital. All the donors signed the Informed Consent Form.
Ethics oversight	The clinical protocol was reviewed and approved by the Clinical Research Ethics Committee of the First Affliated Hospital, College of Medicine, Zhejiang University (2020IIT(85)).

Note that full information on the approval of the study protocol must also be provided in the manuscript.

# Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>

# Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	This is an eight patient exploratory pilot study with a planned infusion dose of 2×10^6 CAR T cells/kg. If this study suggests the safety and feasibility of non-viral PD1-integrated CAR T cell therapy, a larger follow-on trial will be performed according to a standard 3+3 design for a phase I dose-escalation trial.
Data exclusions	In some analyses, the scRNA-seq data of the patient-3 samples were excluded due to an unreliable low CAR+ cell number. The data exclusions were described in the figure legends.
Replication	For the preclinical study, experiments were replicated in at least two independent healthy human donors unless otherwise noted.
Randomization	Randomization is not applicable as this is a phase I, open-label, single-arm study.
Blinding	There was no blinding as a phase I, open-label, single-arm clinical trial was performed.

# Behavioural & social sciences study design

All studies must disclose on these points even when the disclosure is negative.

Study description	Briefly describe the study type including whether data are quantitative, qualitative, or mixed-methods (e.g. qualitative cross-sectional, quantitative experimental, mixed-methods case study).
Research sample	State the research sample (e.g. Harvard university undergraduates, villagers in rural India) and provide relevant demographic information (e.g. age, sex) and indicate whether the sample is representative. Provide a rationale for the study sample chosen. For studies involving existing datasets, please describe the dataset and source.
Sampling strategy	Describe the sampling procedure (e.g. random, snowball, stratified, convenience). Describe the statistical methods that were used to predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient. For qualitative data, please indicate whether data saturation was considered, and what criteria were used to decide that no further sampling was needed.
Data collection	Provide details about the data collection procedure, including the instruments or devices used to record the data (e.g. pen and paper, computer, eye tracker, video or audio equipment) whether anyone was present besides the participant(s) and the researcher, and whether the researcher was blind to experimental condition and/or the study hypothesis during data collection.
Timing	Indicate the start and stop dates of data collection. If there is a gap between collection periods, state the dates for each sample cohort.
Data exclusions	If no data were excluded from the analyses, state so OR if data were excluded, provide the exact number of exclusions and the rationale behind them, indicating whether exclusion criteria were pre-established.
Non-participation	State how many participants dropped out/declined participation and the reason(s) given OR provide response rate OR state that no participants dropped out/declined participation.
Randomization	If participants were not allocated into experimental groups, state so OR describe how participants were allocated to groups, and if allocation was not random, describe how covariates were controlled.

# Ecological, evolutionary & environmental sciences study design

#### All studies must disclose on these points even when the disclosure is negative.

Study description	Briefly describe the study. For quantitative data include treatment factors and interactions, design structure (e.g. factorial, nested, hierarchical), nature and number of experimental units and replicates.
Research sample	Describe the research sample (e.g. a group of tagged Passer domesticus, all Stenocereus thurberi within Organ Pipe Cactus National Monument), and provide a rationale for the sample choice. When relevant, describe the organism taxa, source, sex, age range and any manipulations. State what population the sample is meant to represent when applicable. For studies involving existing datasets, describe the data and its source.
Sampling strategy	Note the sampling procedure. Describe the statistical methods that were used to predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient.
Data collection	Describe the data collection procedure, including who recorded the data and how.
Timing and spatial scale	Indicate the start and stop dates of data collection, noting the frequency and periodicity of sampling and providing a rationale for these choices. If there is a gap between collection periods, state the dates for each sample cohort. Specify the spatial scale from which the data are taken
Data exclusions	If no data were excluded from the analyses, state so OR if data were excluded, describe the exclusions and the rationale behind them, indicating whether exclusion criteria were pre-established.
Reproducibility	Describe the measures taken to verify the reproducibility of experimental findings. For each experiment, note whether any attempts to repeat the experiment failed OR state that all attempts to repeat the experiment were successful.
Randomization	Describe how samples/organisms/participants were allocated into groups. If allocation was not random, describe how covariates were controlled. If this is not relevant to your study, explain why.
Blinding	Describe the extent of blinding used during data acquisition and analysis. If blinding was not possible, describe why OR explain why blinding was not relevant to your study.
Did the study involve field	d work? Yes No

# Field work, collection and transport

Field conditions	Describe the study conditions for field work, providing relevant parameters (e.g. temperature, rainfall).
Location	State the location of the sampling or experiment, providing relevant parameters (e.g. latitude and longitude, elevation, water depth).
Access & import/export	Describe the efforts you have made to access habitats and to collect and import/export your samples in a responsible manner and in compliance with local, national and international laws, noting any permits that were obtained (give the name of the issuing authority, the date of issue, and any identifying information).
Disturbance	Describe any disturbance caused by the study and how it was minimized.

# Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

n/a       Involved in the study       n/a       Involved in the study         Antibodies       ChiP-seq         Eukaryotic cell lines       Flow cytometry         Palaeontology and archaeology       MRI-based neuroimaging         Clinical data       MRI-based neuroimaging         Clinical data       Dual use research of concern         Antibodies used       FITC anti-human CD3 (Biolegend, 300306, Clone HIT3a) APC anti-human CD57 (Biolegend, 309306, Clone HIT3a) APC anti-human CD57 (Biolegend, 309306, Clone HIT3a) APC anti-human CD53 (Biolegend, 309306, Clone HIT3a) APC anti-human CD53 (Biolegend, 355110, Clone KA251) APC anti-human PD1 (Biolegend, 359012, Clone FM2C65) APC anti-human CD53 (Biolegend, 359012, Clone FM2C65) APC anti-human CD54 (Biolegend, 35902, Clone FM2C21) BV421 anti-human CD542 (Biolegend, 35912, Clone FM32) BV421 anti-human CD64 (Biolegend, 300226, Clone HIB3) FITC anti-human CD64 (Biolegend, 30104, Clone DR6-56) APC anti-human CD64 (Biolegend, 30104, Clone DR6-56) APC anti-human CD64 (Biolegend, 317418, Clone CK14) APC anti-human CD64 (Biolegend, 317418, Clone CK14) APC anti-human CD64 (Biolegend, 317418, Clone PA78) BV421 anti-human CD64 (Biolegend, 317418, Clone PA78) APC anti-human CD64 (Biolegend, 317418, Clone PA78) BV421 anti-human CD64 (Biolegend, 317418, Clone PA78) APC anti-human CD64 (Biolegend, 317418, Clone PA78) BV421 anti-human CD79 (Biolegend, 317418, Clone PA78) BV421 anti-human CD64 (Biolegend	Materials & experime	ental systems Methods
Antibodies       ChIP-seq         Eukaryotic cell lines       Flow cytometry         Animals and other organisms       MRI-based neuroimaging         Animals and other organisms       MRI-based neuroimaging         Clinical data       Dual use research of concern         Antibodies used       FITC anti-human CD3 (Biolegend, 300306, Clone HIT3a)         Antibodies used       FITC anti-human CD3 (Biolegend, 309306, Clone HIT3a)         Ap2 canti-human CD3 (Biolegend, 309302, Clone HIT3a)       APC anti-human CD3 (Biolegend, 309302, Clone HIT3a)         Ap2 canti-human CD3 (Biolegend, 309302, Clone HIT3a)       APC anti-human CD3 (Biolegend, 309302, Clone HIT3a)         APC anti-human CD3 (Biolegend, 309302, Clone HIT3a)       APC anti-human CD3 (Biolegend, 309302, Clone HIT3a)         APC anti-human CD3 (Biolegend, 309302, Clone HIT3a)       APC anti-human CD3 (Biolegend, 309302, Clone HIT3a)         APC anti-human CD3 (Biolegend, 309302, Clone HIT3a)       APC anti-human CD4 (Biolegend, 304224, Clone UCH11)         APC anti-human CD3 (Biolegend, 304224, Clone UCH11)       APC anti-human CD42 (Biolegend, 304224, Clone UCH11)         APC anti-human CD3 (Biolegend, 3014, Clone RPA-T8)       BV421 anti-human CD4 (Biolegend, 30142, Clone UPA-T8)         BV421 anti-human CD4 (Biolegend, 30424, Clone UCH11)       APC anti-human CD4 (Biolegend, 30142, Clone RPA-T8)         BV421 anti-human CD4 (Biolegend, 3017405, Clone CVA14)       APC anti-human CD4 (Biolegend, 30	n/a Involved in the study	n/a Involved in the study
Lukaryotic cell lines       Placeontology and archaeology       Placeontology and archaeology         Animals and other organisms       Placeontology and archaeology       Placeontology and archaeology         Clinical data       Placeontology       Placeontology         Clinical data       Placeontology       Placeontology         Dual use research of concern       Placeontology       Placeontology         Antibodies used       FffC anti-human CD3 (Biolegend, 300306, Clone HIT3a) APC anti-human CD3 (Biolegend, 310910, Clone FN50) APC anti-human CD59 (Biolegend, 310910, Clone FN50) APC anti-human CD59 (Biolegend, 35010, Clone MA251) APC anti-human CD59 (Biolegend, 35010, Clone MA251) APC anti-human CD58 (Biolegend, 35012, Clone KH12,2H7) APC anti-human CD54 (Biolegend, 304224, Clone UCH1) APC anti-human CD54 (Biolegend, 304224, Clone UCH1) APC anti-human CD54 (Biolegend, 304224, Clone UCH1) APC anti-human CD54 (Biolegend, 304232, Clone FR5-656) APC anti-human CD54 (Biolegend, 304232, Clone HB30) PrefP-CY*S-5 anti-human CD54 (Biolegend, 30432, Clone HI30) PrefP-CY*S-5 anti-human CD45 (Biolegend, 317416, Clone OKT4) APC anti-human CD45 (Biolegend, 317416, Clone OKT4) APC anti-human CD45 (Biolegend, 317416, Clone OKT4) APC anti-human CD45 (Biolegend, 317416, Clone KPA-T8) BY421 anti-human CD45 (Biolegend, 317416, Clone KPA-T8) APC anti	Antibodies	ChIP-seq
Palacontology and archaeology       Image: Minimals and other organisms         Image: Clinical data       Image: Minimal Clinical data	Eukaryotic cell line	5 Flow cytometry
Animals and other organisms         Clinical data         Clinical data         Dual use research of concern         Antibodies used         FITC anti-human CD3 (Biolegend, 300306, Clone HIT3a)         APC anti-human CD37 (Biolegend, 30910, Clone FNS0)         APC anti-human CD37 (Biolegend, 309210, Clone 4H2-1)         APC anti-human CD37 (Biolegend, 30920, Clone 4H2-1)         APC anti-human CD37 (Biolegend, 30920, Clone 4H2-2H7)         APC anti-human CD37 (Biolegend, 30920, Clone 4H2-2H7)         APC anti-human CD37 (Biolegend, 30920, Clone 4H2-2H7)         APC anti-human CD43 (Biolegend, 309212, Clone 7H2-2H7)         APC anti-human CD43 (Biolegend, 309212, Clone 7H2-2H7)         APC anti-human CD43 (Biolegend, 30422, Clone UCH1)         APC anti-human CD4 (Biolegend, 30422, Clone UCH1)         APC anti-human CD4 (Biolegend, 3012, Clone HIT3A)         FITC anti-human CD4 (Biolegend, 30124, Clone UCH1)         APC anti-human CD4 (Biolegend, 30124, Clone UCH1)         APC anti-human CD4 (Biolegend, 30124, Clone W141)         APC anti-human CD4 (Biolegend, 30124, Clone W141)         APC anti-human CD4 (Biolegend, 317408, Clone OKT4)         APC anti-human CD4 (Biolegend, 30124, Clone W141)         APC anti-human CD4 (Biolegend, 30124, Clone W141)         APC anti-human CD4 (Biolegend, 30124, Clone W141)         APC anti-human CD4 (Biolegend,	Palaeontology and	archaeology MRI-based neuroimaging
Antihals and outches organizations         Clinical data         Dual use research of concern         Antibodies used         FTC anti-human CD3 (Biolegend, 300306, Clone HIT3a)         APC anti-human CD59 (Biolegend, 310910, Clone FN50)         APC anti-human CD59 (Biolegend, 309810, Clone 484-1)         APC anti-human CD25 (Biolegend, 32908, Clone FH12,2H7)         APC anti-human CD53 (Biolegend, 35011, Clone AA251)         APC anti-human D103 (Biolegend, 32909, Clone FH12,2H7)         APC anti-human CD54 (Biolegend, 32012, Clone FH2265)         APC anti-human CD45 (Biolegend, 340212, Clone FH2265)         APC anti-human CD45 (Biolegend, 340212, Clone FH2265)         BY 21 anti-human CD45 (Biolegend, 300312, Clone HIT3A)         FTC anti-human CD4 (Biolegend, 300312, Clone HIT3A)         FTC anti-human CD4 (Biolegend, 30206, Clone PK-40)         APC anti-human CD4 (Biolegend, 317415, Clone CVT4)         APC anti-human CD4 (Biolegend, 31042, Clone HIT3A)         FTC anti-human CD4 (Biolegend, 31042, Clone PK-41)         APC anti-human CD4 (Biolegend, 31042, Clone PK-41)         APC anti-human CD4 (Biolegend, 31042, Clone PK-41)         APC anti-human CD4 (Biolegend, 31042, Clone PK-41)         PC C+CY <sup>WS</sup> 5. 5 anti-human CD4 (Biolegend, 31042, Clone PK-41)         PerCP-CY <sup>WS</sup> 5. 5 anti-human CD4 (Biolegenes, 564050, Clone PR-413)         PerCP-CY <sup>WS</sup> 5. 5 anti-human	Animals and other	
Clinical data         Control data         Dual use research of concern    Antibodies used          FTC anti-human CD3 (Biolegend, 300306, Clone HIT3a)         APC anti-human CD5 (Biolegend, 309310, Clone 484-1)         APC anti-human CD37 (Biolegend, 309310, Clone 484-1)         APC anti-human CD58 (Biolegend, 329908, Clone EH12.2H7)         APC anti-human CD58 (Biolegend, 369112, Clone 7H2C65)         APC anti-human TM3 (Biolegend, 369212, Clone 7H2C65)         APC anti-human TM3 (Biolegend, 30202, Clone HI12.2H7)         APC anti-human TM3 (Biolegend, 30212, Clone 7H2C65)         BV421 anti-human CD45R0 (Biolegend, 304224, Clone UCHL1)         APC anti-human CD45R0 (Biolegend, 304204, Clone UCHL1)         APC anti-human CD45 (Biolegend, 30200, Clone HIB3)         FTC anti-human CD4 (Biolegend, 30200, Clone HIB3)         FTC anti-human CD4 (Biolegend, 30202, Clone HIB3)         FTC anti-human CD4 (Biolegend, 304032, Clone KT4)         APC anti-human CD4 (Biolegend, 304032, Clone HIB3)         PerCA-CYP*5.5 anti-human CD46 (Biolegend, 304032, Clone RPA-T8)         BV421 anti-human CD4 (Biolegend, 304032, Clone RPA-T8)         APC anti-human CD4 (Biolegend, 304032, Clone RPA-T8)         APC anti-human CD4 (Biolegend, 304032, Clone RPA-T8)         APC anti-human CD4 (Biolegend, SPA-18)         APC anti-human CD4 (Biolegend, SPA-18)         AP		
Antibodies         Antibodies used       FITC anti-human CD3 (Biolegend, 300306, Clone HIT3a) APC anti-human CD59 (Biolegend, 309310, Clone 484-1) APC anti-human CD137 (Biolegend, 356110, Clone M-A251) APC anti-human CD138 (Biolegend, 356110, Clone M-A251) APC anti-human LAG3 (Biolegend, 356212, Clone FIA2C65) APC anti-human LAG3 (Biolegend, 345012, Clone FIA2C65) APC anti-human CD169 (Biolegend, 302424, Clone UCH11) APC anti-human CD138 (Biolegend, 304242, Clone HIT3A) FITC anti-human CD169 (Biolegend, 302424, Clone UCH11) APC anti-human CD169 (Biolegend, 302424, Clone HIT3A) FITC anti-human CD169 (Biolegend, 302424, Clone HIT3A) FITC anti-human CD169 (Biolegend, 302424, Clone DKG-56) APC anti-human CD169 (Biolegend, 302424, Clone DKG-56) APC anti-human CD168 (Biolegend, 302424, Clone HIT3A) FITC anti-human CD168 (Biolegend, 302424, Clone MCH41) APC anti-human CD168 (Biolegend, 302424, Clone MCH4) APC anti-human CD46 (Biolegend, 302424, Clone MT3A) FITC anti-human CD46 (Biolegend, 304032, Clone HIT3A) FITC anti-human CD46 (Biolegend, 304032, Clone MI30) PerCP-CY <sup>W</sup> 5.5 anti-human CD46 (Biolegend, 317406, Clone OKT4) APC anti-human CD46 (Biolegend, 317416, Clone OKT4) APC anti-human CD46 (Biolegend, 304032, Clone HI30) PerCP-CY <sup>W</sup> 5.5 anti-human CD46 (Biolegend, 304032, Clone HI30) PerCP-CY <sup>W</sup> 5.5 anti-human CD46 (Biolegend, 304032, Clone MPA-T8) APC anti-human CD46 (Biolegend, 304032, Clone MPA-T8) APC anti-human CD46 (Biolegend, 304032, Clone MI410) Anti-human CD50 (Biolynx, 11045, Clone BP6046) Anti-human PD-11 (Agilent, pharmDx, Clone 22C3)		
Antibodies used       FITC anti-human CD3 (Biolegend, 300306, Clone HIT3a) APC anti-human CD69 (Biolegend, 310910, Clone FM50) APC anti-human CD69 (Biolegend, 309810, Clone 484-1) APC anti-human CD25 (Biolegend, 309810, Clone 484-1) APC anti-human CD25 (Biolegend, 359112, Clone FM2C55) APC anti-human CD33 (Biolegend, 359212, Clone FM2C45) APC anti-human CD45 (Biolegend, 349212, Clone FM2C45) APC anti-human CD45 (Biolegend, 349212, Clone FM2C45) APC anti-human CD45 (Biolegend, 349212, Clone FM2C45) BV421 anti-human CD45 (Biolegend, 304224, Clone UCHL1) APC anti-human CD45 (Biolegend, 304224, Clone UCHL1) APC anti-human CD45 (Biolegend, 304224, Clone UCHL1) APC anti-human CD46 (Biolegend, 304224, Clone UCHL1) APC anti-human CD4 (Biolegend, 304220, Clone HIB19) FITC anti-human CD4 (Biolegend, 304220, Clone HIB19) FITC anti-human CD4 (Biolegend, 304032, Clone HIB19) BV421 anti-human CD4 (Biolegend, 304032, Clone HIB19) PerCP-Cy <sup>W5</sup> , 5. anti-human CD45 (Biolegend, 304032, Clone HI30) PerCP-Cy <sup>W5</sup> , 5. anti-human CD4 (BD Biosciences, 560455, Clone RPA-T8) BV421 anti-human CD8 (BD Biosciences, 560428, Clone RPA-T8) BV421 anti-human CD4 (BD Biosciences, 560428, Clone RPA-T8) BV421 anti-human CD4 (BD Biosciences, 560455, Clone RPA-T8) BV421 anti-human CD4 (BD Biosciences, 560455, Clone RPA-T8) BV421 anti-human CD4 (BD Biosciences, 560428, Clone RPA-T8) BV421 anti-human CD4 (BD Biosciences, 560458, Clone RPA-T8) BV421 anti-human CD4 (BD Biosciences, 560458, Clone RPA-T8) APC anti-human CD4 (BD Biosciences, 560458, Clone RPA-T8) APC anti-human CD4 (Biolegend, 304032, Clone BF046) Anti-human PD-L1 (Aglient, pharmDx, Clone 22C3)         Validation       All antibodies used in this study are commercially available. Antibody validations were performed by the suppliers and the information is provided on the website and product information datasheets. The certificate of analysis (CoA) was provided for the qualitly assurance of each antibody lot.	Dual use research o	of concern
Antibodies used       FITC anti-human CD3 (Biolegend, 300306, Clone HIT3a) APC anti-human CD59 (Biolegend, 309310, Clone FNS0) APC anti-human CD137 (Biolegend, 309310, Clone 484-1) APC anti-human CD135 (Biolegend, 309310, Clone 484-1) APC anti-human DD1 (Biolegend, 309310, Clone FN251) APC anti-human LAG3 (Biolegend, 359212, Clone 7H2C65) APC anti-human LAG3 (Biolegend, 345012, Clone FR3-2E2) BV421 anti-human CD45R0 (Biolegend, 304204, Clone DREG-56) APC anti-human CD3 (Biolegend, 30212, Clone HIT3A) FITC anti-human CD13 (Biolegend, 30212, Clone HIT3A) FITC anti-human CD4 (Biolegend, 301014, Clone PRA-T8) BV421 anti-human CD4 (BD Biosciences, 560428, Clone HI30) PerCP-Cy <sup>W5</sup> .5 anti-human CD4 (BD Biosciences, 560428, Clone RPA-T4) BV421 anti-human CD4 (BD Biosciences, 560428, Clone RPA-T8) APC anti-human CD4 (BD RASCERS) APC anti-human CD4 (BD		
Antibodies usedFITC anti-human CD3 (Biolegend, 300306, Clone HI3a) APC anti-human CD13 (Biolegend, 310910, Clone FN50) APC anti-human CD13 (Biolegend, 309810, Clone FN50) APC anti-human CD15 (Biolegend, 329908, Clone EH12.2H7) APC anti-human PD1 (Biolegend, 329908, Clone EH12.2H7) APC anti-human LAG3 (Biolegend, 345012, Clone 7H2C65) APC anti-human CD45P0 (Biolegend, 345012, Clone FN2-E2) BV421 anti-human CD45P0 (Biolegend, 304224, Clone UCH11) APC anti-human CD45 (Biolegend, 304224, Clone UCH11) APC anti-human CD45 (Biolegend, 304204, Clone UCH11) APC anti-human CD4 (Biolegend, 302206, Clone HI30) FITC anti-human CD4 (Biolegend, 317416, Clone OKT4) APC anti-human CD4 (Biolegend, 317416, Clone CNT4) APC anti-human CD45 (Biolegend, 304032, Clone HI30) PerCP-Cy <sup>WS</sup> -S. anti-human CD45 (BD Biosciences, 564105, Clone HI30) PerCP-Cy <sup>WS</sup> -S. anti-human CD45 (BD Biosciences, 56050, Clone RPA-T8) BV421 anti-human CD4 (BD Biosciences, 56428, Clone RPA-T8) APC anti-human PD-L1 (Agil	Antibodies	
APC anti-human CD69 (Biolegend, 310910, Clone FN50)APC anti-human CD137 (Biolegend, 356110, Clone 4A-1)APC anti-human CD25 (Biolegend, 356110, Clone M-A251)APC anti-human PD1 (Biolegend, 329908, Clone EH12.2H7)APC anti-human CAG3 (Biolegend, 345012, Clone 748-2E2)BV421 anti-human CD45R0 (Biolegend, 345012, Clone 748-2E2)BV421 anti-human CD45R0 (Biolegend, 300312, Clone HIT3A)APC anti-human CD51, (Biolegend, 300312, Clone HIT3A)FITC anti-human CD61 (Biolegend, 30226, Clone HIB19)FITC anti-human CD4 (Biolegend, 30121, Clone RPA-78)BV421 anti-human CD4 (Biolegend, 30206, Clone HIB19)FITC anti-human CD4 (Biolegend, 317408, Clone OKT4)APC anti-human CD4 (Biolegend, 30114, Clone RPA-78)BV421 anti-human CD4 (Biolegend, 30104, Clone RPA-78)BV421 anti-human CD4 (BD Biosciences, 564105, Clone HI30)PerCP-Cy <sup>W</sup> 5.5 anti-human CD4 (BD Biosciences, 566428, Clone RPA-74)BV421 anti-human CD4 (Bo Biosciences, 566428, Clone RPA-74)BV421 anti-human CD4 (BD Biosciences, 564105, Clone HI30)PerCP-Cy <sup>W</sup> 5.5 anti-human CD4 (BD Biosciences, 566428, Clone RPA-74)BV421 anti-human CD4 (BD Biosciences, 566428, Clone RPA-74)BV421 anti-human CD4 (BD Biosciences, 56428, Clone RPA-74)BV421 anti-human CD4 (BO Biosciences, 56428, Clone RPA-78)	Antibodies used	FITC anti-human CD3 (Biolegend, 300306, Clone HIT3a)
<ul> <li>APC anti-human CD137 (Biolegend, 309810, Clone 484-1)</li> <li>APC anti-human CD25 (Biolegend, 329908, Clone EH12.2H7)</li> <li>APC anti-human D10 (Biolegend, 349012, Clone 7H2C65)</li> <li>APC anti-human TIM3 (Biolegend, 346012, Clone 7H2C65)</li> <li>APC anti-human CD45RO (Biolegend, 304224, Clone UCHL1)</li> <li>APC anti-human CD52L (Biolegend, 304809, Clone UCHL1)</li> <li>APC anti-human CD52L (Biolegend, 304302, Clone HIT3A)</li> <li>FITC anti-human CD19 (Biolegend, 317408, Clone OKT4)</li> <li>APC anti-human CD4 (Biolegend, 317408, Clone OKT4)</li> <li>APC anti-human CD8 (Biolegend, 30432, Clone HIT3A)</li> <li>FITC anti-human CD4 (Biolegend, 317408, Clone OKT4)</li> <li>APC anti-human CD8 (Biolegend, 30403, Clone NT4)</li> <li>APC anti-human CD4 (Biolegend, 30403, Clone NT4)</li> <li>APC anti-human CD4 (Biolegend, 30432, Clone HI30)</li> <li>PerCP-CY<sup>W5</sup>.5 anti-human CD4 (BD Biosciences, 564105, Clone HI30)</li> <li>PerCP-CY<sup>W5</sup>.5 anti-human CD4 (BD Biosciences, 56050, Clone RPA-T8)</li> <li>BV421 anti-human CD4 (BD Biosciences, 560450, Clone RPA-T4)</li> <li>BV421 anti-human CD4 (BD Biosciences, 560405, Clone RPA-T8)</li> <li>APC anti-human CD4 (BD Biosciences, 560406, Anti-human CD4 (BD Biosciences, 52023)</li> <li>Validation</li> <li>All antibodies used in this study are commercially available. Antibody validations were performed by the suppliers and the information is provided on the website and product information datasheets. The certificate of analysis (CoA) was provided for the quality assurance of each antibody lot.</li> </ul>		APC anti-human CD69 (Biolegend, 310910, Clone FN50)
APC anti-human DD2 (Biolegend, 35911), Clone WH221)         APC anti-human LG3 (Biolegend, 32908, Clone EH12.2H7)         APC anti-human LG3 (Biolegend, 345012, Clone 7H2C65)         APC anti-human CD45R0 (Biolegend, 34204, Clone UCHL1)         APC anti-human CD51 (Biolegend, 304224, Clone UCHL1)         APC anti-human CD52 (Biolegend, 304224, Clone UCHL1)         APC anti-human CD62 (Biolegend, 300312, Clone HIT3A)         FITC anti-human CD19 (Biolegend, 302206, Clone HIB19)         FITC anti-human CD4 (Biolegend, 317408, Clone OKT4)         APC anti-human CD4 (Biolegend, 317408, Clone OKT4)         APC anti-human CD4 (Biolegend, 304032, Clone HIB19)         FITC anti-human CD4 (Biolegend, 317408, Clone OKT4)         APC anti-human CD4 (Biolegend, 304032, Clone HIB19)         Per Canti-human CD4 (Biolegend, 304032, Clone HIB19)         Per Canti-human CD4 (Biolegend, 304032, Clone HIB10)         Per CP-Cy <sup>NS</sup> .5. anti-human CD4 (BD Biosciences, 564105, Clone HI30)         Per CP-Cy <sup>NS</sup> .5. anti-human CD4 (BD Biosciences, 564055, Clone RPA-T4)         BV421 anti-human CD8 (BD Biosciences, 562428, Clone RPA-T8)         APC anti-human PD-11 (ThermoFisher, 17-5983-41, Clone MIH1)         Anti-human PD-11 (Agilent, pharmDx, Clone 22C3)         Validation       All antibodies used in this study are commercially available. Antibody validations were performed by the suppliers and the information is provided on the website and product information datasheets. The certifi		APC anti-human CD137 (Biolegend, 309810, Clone 4B4-1)
APC anti-human FD1 (Biolegend, 3629:02, Clone 7H2:C47)         APC anti-human LAG3 (Biolegend, 345012, Clone 7H2:C45)         APC anti-human CD45R0 (Biolegend, 304224, Clone UCHL1)         APC anti-human CD62L (Biolegend, 304322, Clone HCH11)         APC anti-human CD62L (Biolegend, 30312, Clone HIT3A)         FITC anti-human CD19 (Biolegend, 302206, Clone HIB19)         FITC anti-human CD4 (Biolegend, 317408, Clone OKT4)         APC anti-human CD4 (Biolegend, 317416, Clone OKT4)         APC anti-human CD4 (Biolegend, 304032, Clone HIB19)         FITC anti-human CD4 (Biolegend, 304032, Clone HI30)         PerCP-Cy™5.5 anti-human CD4 (BD Biosciences, 564105, Clone HI30)         PerCP-Cy™5.5 anti-human CD4 (BD Biosciences, 56050, Clone RPA-T8)         BV421 anti-human CD8 (BD Biosciences, 562428, Clone RPA-T8)         PCP-Cy™5.5 anti-human CD4 (BD Biosciences, 562428, Clone RPA-T8)         APC anti-human PD-L1 (ThermoFisher, 17-5983-41, Clone MIH1)         Anti-human PD-L1 (Agilent, pharmDx, Clone 22C3)		APC anti-human CD25 (Biolegend, 356110, Clone M-A251) APC anti-human DD1 (Biologend, 220008, Clone EH12, 2H7)
APC anti-human TiM3 (Biolegend, 345012, Clone T38-2E2)BV421 anti-human CD45RO (Biolegend, 304204, Clone UCHL1)APC anti-human CD52L (Biolegend, 304809, Clone DREG-56)APC anti-human CD3 (Biolegend, 300312, Clone HIT3A)FITC anti-human CD19 (Biolegend, 302206, Clone HIB19)FITC anti-human CD4 (Biolegend, 317408, Clone OKT4)APC anti-human CD4 (Biolegend, 304032, Clone HIB19)FITC anti-human CD4 (Biolegend, 304032, Clone HI30)PerCP-Cy™5.5 anti-human CD4 (BD Biosciences, 564105, Clone HI30)PerCP-Cy™5.5 anti-human CD4 (BD Biosciences, 564050, Clone RPA-T8)BV421 anti-human DC4 (BD Biosciences, 56428, Clone RPA-T8)APC anti-human DC19 (BD Biosciences, 56428, Clone RPA-T8)APC anti-human DC19 (BD Biosciences, 56428, Clone RPA-T8)APC anti-human DC11 (ThermoFisher, 17-5983-41, Clone MIH1)Anti-human DD-L1 (Agilent, pharmDx, Clone 22C3)ValidationAll antibodies used in this study are commercially available. Antibody validations were performed by the suppliers and the information is provided on the website and product information datasheets. The certificate of analysis (CoA) was provided for the quality assurance of each antibody lot.		APC anti-human LAG3 (Biolegend, 369212, Clone 7H2C65)
BV421 anti-human CD45RO (Biolegend, 304224, Clone UCHL1)APC anti-human CD3 (Biolegend, 304809, Clone DREG-56)APC anti-human CD3 (Biolegend, 300312, Clone HIT3A)FITC anti-human CD19 (Biolegend, 30206, Clone HIB19)FITC anti-human CD4 (Biolegend, 317408, Clone OKT4)APC anti-human CD4 (Biolegend, 304032, Clone HIB19)FITC anti-human CD4 (Biolegend, 304032, Clone HIB19)FITC anti-human CD4 (Biolegend, 317416, Clone OKT4)APC anti-human CD4 (Biolegend, 304032, Clone HI30)PerCP-CY™5.5 anti-human CD4 (Biolegend, 304032, Clone HI30)PerCP-CY™5.5 anti-human CD4 (BD Biosciences, 560650, Clone RPA-T8)BV421 anti-human CD4 (BD Biosciences, 560650, Clone RPA-T4)BV421 anti-human CD4 (BD Biosciences, 560650, Clone RPA-T4)BV421 anti-human CD4 (BD Biosciences, 562428, Clone RPA-T8)APC anti-human CD1 (Biolynx, 11045, Clone BP6046)Anti-human CD1 (Biolynx, 11045, Clone BP6046)Anti-human PD-L1 (Agilent, pharmDx, Clone 22C3)ValidationAll antibodies used in this study are commercially available. Antibody validations were performed by the suppliers and the information is provided on the website and product information datasheets. The certificate of analysis (CoA) was provided for the quality assurance of each antibody lot.		APC anti-human TIM3 (Biolegend, 345012, Clone F38-2E2)
APC anti-human CD62L (Biolegend, 304809, Clone DREG-56)APC anti-human CD3 (Biolegend, 302312, Clone HIT3A)FITC anti-human CD19 (Biolegend, 302206, Clone HIB19)FITC anti-human CD4 (Biolegend, 317408, Clone OKT4)APC anti-human CD4 (Biolegend, 317416, Clone OKT4)APC anti-human CD4 (Biolegend, 317416, Clone OKT4)APC anti-human CD4 (Biolegend, 301014, Clone RPA-T8)BV421 anti-human CD45 (Biolegend, 304032, Clone HI30)PerCP-Cy™5.5 anti-human CD45 (BD Biosciences, 564105, Clone HI30)PerCP-Cy™5.5 anti-human CD4 (BD Biosciences, 560650, Clone RPA-T4)BV421 anti-human CD8 (BD Biosciences, 560428, Clone RPA-T8)APC anti-human PD-L1 (ThermoFisher, 17-5983-41, Clone MIH1)Anti-human CD19 (Biolynx, 11045, Clone BP6046)Anti-human PD-L1 (Agilent, pharmDx, Clone 22C3)ValidationAll antibodies used in this study are commercially available. Antibody validations were performed by the suppliers and the information is provided on the website and product information datasheets. The certificate of analysis (CoA) was provided for the quality assurance of each antibody lot.		BV421 anti-human CD45RO (Biolegend, 304224, Clone UCHL1)
APC anti-human CD3 (Biolegend, 300312, Clone HIT3A)FITC anti-human CD19 (Biolegend, 302206, Clone HIB19)FITC anti-human CD4 (Biolegend, 317408, Clone OKT4)APC anti-human CD4 (Biolegend, 317416, Clone OKT4)APC anti-human CD4 (Biolegend, 301014, Clone RPA-T8)BV421 anti-human CD45 (Biolegend, 304032, Clone HI30)PerCP-Cy™5.5 anti-human CD4 (BD Biosciences, 564105, Clone HI30)PerCP-Cy™5.5 anti-human CD4 (BD Biosciences, 56050, Clone RPA-T4)BV421 anti-human CD8 (BD Biosciences, 562428, Clone RPA-T8)APC anti-human CD19 (Biolynx, 11045, Clone BP6046)Anti-human PD-L1 (Agilent, pharmDx, Clone 22C3)ValidationAll antibodies used in this study are commercially available. Antibody validations were performed by the suppliers and the information is provided on the website and product information datasheets. The certificate of analysis (CoA) was provided for the quality assurance of each antibody lot.		APC anti-human CD62L (Biolegend, 304809, Clone DREG-56)
<ul> <li>FITC anti-human CD19 (Biolegend, 302206, Clone HIB19)</li> <li>FITC anti-human CD4 (Biolegend, 317408, Clone OKT4)</li> <li>APC anti-human CD4 (Biolegend, 317416, Clone OKT4)</li> <li>APC anti-human CD8 (Biolegend, 301014, Clone RPA-T8)</li> <li>BV421 anti-human CD45 (Biolegend, 304032, Clone HI30)</li> <li>PerCP-Cy™5.5 anti-human CD4 (BD Biosciences, 564105, Clone RPA-T4)</li> <li>BV421 anti-human CD8 (BD Biosciences, 560650, Clone RPA-T4)</li> <li>BV421 anti-human CD8 (BD Biosciences, 562428, Clone RPA-T8)</li> <li>APC anti-human CD19 (Biolynx, 11045, Clone BP6046)</li> <li>Anti-human PD-L1 (Agilent, pharmDx, Clone 22C3)</li> <li>Validation</li> <li>All antibodies used in this study are commercially available. Antibody validations were performed by the suppliers and the information is provided on the website and product information datasheets. The certificate of analysis (CoA) was provided for the quality assurance of each antibody lot.</li> </ul>		APC anti-human CD3 (Biolegend, 300312, Clone HIT3A)
HIC anti-human CD4 (Biolegend, 31/408, Clone OK14)APC anti-human CD4 (Biolegend, 317416, Clone OKT4)APC anti-human CD8 (Biolegend, 301014, Clone RPA-T8)BV421 anti-human CD45 (Biolegend, 304032, Clone HI30)PerCP-Cy™5.5 anti-human CD45 (BD Biosciences, 560650, Clone HI30)PerCP-Cy™5.5 anti-human CD4 (BD Biosciences, 560650, Clone RPA-T4)BV421 anti-human CD8 (BD Biosciences, 560650, Clone RPA-T4)BV421 anti-human CD8 (BD Biosciences, 562428, Clone RPA-T8)APC anti-human CD19 (Biolynx, 11045, Clone BP6046)Anti-human PD-L1 (Agilent, pharmDx, Clone 22C3)ValidationAll antibodies used in this study are commercially available. Antibody validations were performed by the suppliers and theinformation is provided on the website and product information datasheets. The certificate of analysis (CoA) was provided for thequality assurance of each antibody lot.		FITC anti-human CD19 (Biolegend, 302206, Clone HIB19)
APC anti-human CD4 (Biolegend, 31/416, Clone OK14)         APC anti-human CD8 (Biolegend, 301014, Clone RPA-T8)         BV421 anti-human CD45 (Bolegend, 304032, Clone HI30)         PerCP-CyTM5.5 anti-human CD45 (BD Biosciences, 564105, Clone HI30)         PerCP-CyTM5.5 anti-human CD4 (BD Biosciences, 560650, Clone RPA-T4)         BV421 anti-human CD8 (BD Biosciences, 562428, Clone RPA-T8)         APC anti-human CD19 (BD Biosciences, 562428, Clone MIH1)         Anti-human PD-L1 (ThermoFisher, 17-5983-41, Clone MIH1)         Anti-human PD-L1 (Agilent, pharmDx, Clone 22C3)         Validation         All antibodies used in this study are commercially available. Antibody validations were performed by the suppliers and the information is provided on the website and product information datasheets. The certificate of analysis (CoA) was provided for the quality assurance of each antibody lot.		HIC anti-human CD4 (Biolegend, 31/408, Clone OK14)
Validation       All antibodies used in this study are commercially available. Antibody validations were performed by the suppliers and the information is provided on the website and product information datasheets. The certificate of analysis (CoA) was provided for the quality assurance of each antibody lot.		APC anti-numan CD4 (Biologond, 31/416, Clone OK14) APC anti-human CD2 (Biologond, 201014, Clone RPA T2)
Validation       All antibodies used in this study are commercially available. Antibody validations were performed by the suppliers and the information is provided on the website and product information datasheets. The certificate of analysis (CoA) was provided for the quality assurance of each antibody lot.		BV421 anti-human CD45 (Biolegend, 304032, Clone HI30)
PerCP-Cy™5.5 anti-human CD4 (BD Biosciences, 560650, Clone RPA-T4)         BV421 anti-human CD8 (BD Biosciences, 562428, Clone RPA-T8)         APC anti-human PD-L1 (ThermoFisher, 17-5983-41, Clone MIH1)         Anti-human CD19 (Biolynx, I1045, Clone BP6046)         Anti-human PD-L1 (Agilent, pharmDx, Clone 22C3)         Validation         All antibodies used in this study are commercially available. Antibody validations were performed by the suppliers and the information is provided on the website and product information datasheets. The certificate of analysis (CoA) was provided for the quality assurance of each antibody lot.		PerCP-Cv™5.5 anti-human CD45 (BD Biosciences, 564105, Clone HI30)
BV421 anti-human CD8 (BD Biosciences, 562428, Clone RPA-T8)         APC anti-human PD-L1 (ThermoFisher, 17-5983-41, Clone MIH1)         Anti-human CD19 (Biolynx, I1045, Clone BP6046)         Anti-human PD-L1 (Agilent, pharmDx, Clone 22C3)         Validation         All antibodies used in this study are commercially available. Antibody validations were performed by the suppliers and the information is provided on the website and product information datasheets. The certificate of analysis (CoA) was provided for the quality assurance of each antibody lot.		PerCP-Cy™5.5 anti-human CD4 (BD Biosciences, 560650, Clone RPA-T4)
APC anti-human PD-L1 (ThermoFisher, 17-5983-41, Clone MIH1) Anti-human CD19 (Biolynx, I1045, Clone BP6046) Anti-human PD-L1 (Agilent, pharmDx, Clone 22C3) All antibodies used in this study are commercially available. Antibody validations were performed by the suppliers and the information is provided on the website and product information datasheets. The certificate of analysis (CoA) was provided for the quality assurance of each antibody lot.		BV421 anti-human CD8 (BD Biosciences, 562428, Clone RPA-T8)
Anti-human CD19 (Biolynx, I1045, Clone BP6046) Anti-human PD-L1 (Agilent, pharmDx, Clone 22C3) All antibodies used in this study are commercially available. Antibody validations were performed by the suppliers and the information is provided on the website and product information datasheets. The certificate of analysis (CoA) was provided for the quality assurance of each antibody lot.		APC anti-human PD-L1 (ThermoFisher, 17-5983-41, Clone MIH1)
Anti-human PD-L1 (Agilent, pharmDx, Clone 22C3) Validation All antibodies used in this study are commercially available. Antibody validations were performed by the suppliers and the information is provided on the website and product information datasheets. The certificate of analysis (CoA) was provided for the quality assurance of each antibody lot.		Anti-human CD19 (Biolynx, I1045, Clone BP6046)
Validation All antibodies used in this study are commercially available. Antibody validations were performed by the suppliers and the information is provided on the website and product information datasheets. The certificate of analysis (CoA) was provided for the quality assurance of each antibody lot.		Anti-human PD-L1 (Agilent, pharmDx, Clone 22C3)
information is provided on the website and product information datasheets. The certificate of analysis (CoA) was provided for the quality assurance of each antibody lot.	Validation	All antibodies used in this study are commercially available. Antibody validations were performed by the suppliers and the
quality assurance of each antibody lot.		information is provided on the website and product information datasheets. The certificate of analysis (CoA) was provided for the
		quality assurance of each antibody lot.

### Eukaryotic cell lines

Policy information about <u>ce</u>	Il lines and Sex and Gender in Research
Cell line source(s)	293T (CRL-3216 <sup>™</sup> ) and Nalm-6 (CRL-3273 <sup>™</sup> ) cells were purchased from ATCC. Raji cells were purchased from Cell Bank of Chinese Academy of Sciences.
Authentication	293T and Nalm-6 cells were directly purchased from ATCC with certification. 293T, Nalm-6 and Raji cells were authenticated

Authentication	by STR profiling by GENEWIZ Co., Ltd.
Authentication	

Mycoplasma contamination All cell lines used were tested negative for mycoplasma contamination.

Commonly misidentified lines (See ICLAC register)

## Palaeontology and Archaeology

Specimen provenance	Provide provenance information for specimens and describe permits that were obtained for the work (including the name of the issuing authority, the date of issue, and any identifying information). Permits should encompass collection and, where applicable, export.
Specimen deposition	Indicate where the specimens have been deposited to permit free access by other researchers.
Dating methods	If new dates are provided, describe how they were obtained (e.g. collection, storage, sample pretreatment and measurement), where they were obtained (i.e. lab name), the calibration program and the protocol for quality assurance OR state that no new dates are provided.
Tick this box to confi	rm that the raw and calibrated dates are available in the paper or in Supplementary Information.
Ethics oversight	Identify the organization(s) that approved or provided guidance on the study protocol, OR state that no ethical approval or guidance was required and explain why not.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Animals and other research organisms

Policy information about studies involving animals; <u>ARRIVE guidelines</u> recommended for reporting animal research, and <u>Sex and Gender in</u> <u>Research</u>

Laboratory animals	For the experiment comparing LV-19bbz and AAVS1-19bbz groups at a high infusion dose, we used 6- to 8-week-old B-NDG (NOD.CB17-Prkdcscidll2rgtm1/Bcgen) male mice (Biocytogen). For other experiments, we used 6- to 9-week-old NCG (NOD/ ShiLtJGpt-Prkdcem26Cd52ll2rgem26Cd22/Gpt) female mice (GemPharmatech).
Wild animals	N/A
Reporting on sex	Only one sex was used in the individual mouse experiments according to the general knowledge in the field. The disaggregated sex data and overall numbers were provided in Results.
Field-collected samples	N/A
Ethics oversight	All animal experiments were conducted in compliance with "Guide for the Care and Use of Laboratory Animals (2011)" issued by the National Research Council (USA), "Laboratory Animal Administration Regulation (2017)" issued by the National Science and Technology Committee (China), and the laboratory animal administration regulations (Shanghai, Jiangsu). The care and the use of animals were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of the East China Normal University Center for Animal Research or InnoStar Bio-tech Nantong Co., Ltd.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Clinical data

Policy information about <u>cl</u>	inical studies
All manuscripts should comply	with the ICMJE guidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions.
Clinical trial registration	ClinicalTrials.gov (NCT04213469)
Study protocol	The study protocol was described in Methods.
Data collection	Clinflash EDC, an electronic data capture system, was used in this study. All data collection was assured to be complete and accurate in the electronic case report forms according to the protocol. All data collected from April 2020.
Outcomes	The primary endpoints of this study were safety and feasibility. Secondary endpoint was efficacy. Exploration objectives included the assessments of in vivo persistence and peak blood levels of PD1-19bbz cells.

## Dual use research of concern

Policy information about <u>dual use research of concern</u>

Could the accidental, deliberate or reckless misuse of agents or technologies generated in the work, or the application of information presented in the manuscript, pose a threat to:



#### Experiments of concern

Does the work involve any of these experiments of concern:

No	Yes
	Demonstrate how to render a vaccine ineffective
	Confer resistance to therapeutically useful antibiotics or antiviral agents
	Enhance the virulence of a pathogen or render a nonpathogen virulent
	Increase transmissibility of a pathogen
	Alter the host range of a pathogen
	Enable evasion of diagnostic/detection modalities
	Enable the weaponization of a biological agent or toxin
	Any other potentially harmful combination of experiments and agents

## ChIP-seq

#### Data deposition

Confirm that both raw and final processed data have been deposited in a public database such as GEO.

Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

Data access links May remain private before publication.	For "Initial submission" or "Revised version" documents, provide reviewer access links. For your "Final submission" document, provide a link to the deposited data.
Files in database submission	Provide a list of all files available in the database submission.
Genome browser session (e.g. <u>UCSC</u> )	Provide a link to an anonymized genome browser session for "Initial submission" and "Revised version" documents only, to enable peer review. Write "no longer applicable" for "Final submission" documents.

#### Methodology

Replicates	Describe the experimental replicates, specifying number, type and replicate agreement.
Sequencing depth	Describe the sequencing depth for each experiment, providing the total number of reads, uniquely mapped reads, length of reads and whether they were paired- or single-end.
Antibodies	Describe the antibodies used for the ChIP-seq experiments; as applicable, provide supplier name, catalog number, clone name, and lot number.
Peak calling parameters	Specify the command line program and parameters used for read mapping and peak calling, including the ChIP, control and index files used.
Data quality	Describe the methods used to ensure data quality in full detail, including how many peaks are at FDR 5% and above 5-fold enrichment.
Software	Describe the software used to collect and analyze the ChIP-seq data. For custom code that has been deposited into a community repository, provide accession details.

## Flow Cytometry

#### Plots

Confirm that:

 $\square$  The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).

The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).

All plots are contour plots with outliers or pseudocolor plots.

A numerical value for number of cells or percentage (with statistics) is provided.

#### Methodology

Sample preparation	Cell culture and the procedures of sample preparation and collection are described in Methods. Cells were pre-washed and incubated with antibodies for 30 minutes on ice. After washing twice, samples were analyzed or sorted by flow cytometry.
Instrument	LSRFortessa (BD Biosciences) or DxFLEX Flow Cytometer (BECKMAN COULTER) for flow cytometry analysis. FACSAria II (BD Biosciences) for FACS.
Software	FlowJo (version 10) was used for flow cytometry data analysis.
Cell population abundance	For Sanger sequencing of AAVS1-19bbz and PD1-19bbz samples and genotyping of PD1-19bbz cells, CAR+ cells were sorted by FACS in advance.
Gating strategy	FSC-A/SSC-A plots were used to determine cell population gates. FSC-A/FSC-H plots were then used to determine singlet gates. The 7-AAD viability dye was used to distinguish live cells from dead cells. Additional gating was performed as described in the figure legends for individual experiments.

Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.

## Magnetic resonance imaging

#### Experimental design

Experimental design		
Design type	Indicate task or resting state; event-related or block design.	
Design specifications	Specify the number of blocks, trials or experimental units per session and/or subject, and specify the length of each trial or block (if trials are blocked) and interval between trials.	
Behavioral performance measure	es State number and/or type of variables recorded (e.g. correct button press, response time) and what statistics were used to establish that the subjects were performing the task as expected (e.g. mean, range, and/or standard deviation across subjects).	
Acquisition		
Imaging type(s)	Specify: functional, structural, diffusion, perfusion.	
Field strength	Specify in Tesla	
Sequence & imaging parameters	Specify the pulse sequence type (gradient echo, spin echo, etc.), imaging type (EPI, spiral, etc.), field of view, matrix size, slice thickness, orientation and TE/TR/flip angle.	
Area of acquisition	State whether a whole brain scan was used OR define the area of acquisition, describing how the region was determined.	
Diffusion MRI Used	Not used	
Preprocessing		
Preprocessing software	Provide detail on software version and revision number and on specific parameters (model/functions, brain extraction, segmentation, smoothing kernel size, etc.).	
Normalization	If data were normalized/standardized, describe the approach(es): specify linear or non-linear and define image types used for transformation OR indicate that data were not normalized and explain rationale for lack of normalization.	
Normalization template	Describe the template used for normalization/transformation, specifying subject space or group standardized space (e.g. original Talairach, MNI305, ICBM152) OR indicate that the data were not normalized.	
Describe your procedure(s) for artifact and structured noise removal, specifying motion parameters, tissue signals an physiological signals (heart rate, respiration).		

Define your software and/or method and criteria for volume censoring, and state the extent of such censoring.

## Statistical modeling & inference

Model type and settings	Specify type (mass univariate, multivariate, RSA, predictive, etc.) and describe essential details of the model at the first and second levels (e.g. fixed, random or mixed effects; drift or auto-correlation).	
Effect(s) tested	Define precise effect in terms of the task or stimulus conditions instead of psychological concepts and indicate whether ANOVA or factorial designs were used.	
Specify type of analysis: Whole brain ROI-based Both		
Statistic type for inference (See <u>Eklund et al. 2016</u> )	Specify voxel-wise or cluster-wise and report all relevant parameters for cluster-wise methods.	
Correction	Describe the type of correction and how it is obtained for multiple comparisons (e.g. FWE, FDR, permutation or Monte Carlo).	
Models & analysis		

#### Ν )

n/a       Involved in the study         Involved in the study         Functional and/or effective connectivity         Graph analysis         Nultivariate modeling or predictive analysis		
Eunctional and/or effective connectivity	Report the measures of dependence used and the model details (e.a. Pearson correlation, partial correlation,	
	mutual information).	
Graph analysis	Report the dependent variable and connectivity measure, specifying weighted graph or binarized graph, subject- or group-level, and the global and/or node summaries used (e.g. clustering coefficient, efficiency, etc.).	
Multivariate modeling and predictive analysis	Specify independent variables, features extraction and dimension reduction, model, training and evaluation metrics	